Quinolone derivative of macrolide as well as preparation method and application of quinolone derivative
By designing macrocyclic lactone quinolone derivatives, the problem of poor treatment efficacy of existing antibiotics against drug-resistant strains has been solved, achieving effective treatment of erythromycin and telithromycin-resistant strains and exhibiting dual-target antibacterial effects.
Patent Information
- Application Number
- CN202410883573.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-02
- Publication Date
- 2026-01-06
AI Technical Summary
Existing macrolide antibiotics such as erythromycin and telithromycin are not very effective against drug-resistant strains, making it difficult to effectively treat infections caused by these strains.
A macrolide quinolone derivative was developed, which, through specific structural modifications, enhances dual-targeting activity against ribosomes and topoisomerases, providing antibacterial activity against erythromycin and telithromycin-resistant strains.
This compound can effectively treat infections caused by pathogens resistant to erythromycin and telithromycin, exhibiting good antibacterial and anti-inflammatory effects, and simultaneously acting on both ribosomes and topoisomerases.
Smart Images

Figure BDA0004925518240000011 
Figure BDA0004925518240000025 
Figure BDA0004925518240000026
Abstract
Description
Technical Field
[0001] This invention relates to the fields of chemical synthesis and pharmaceuticals, specifically to a macrolide quinolone derivative, its preparation method, and its application. Background Technology
[0002] Macrolide-lincosamide-streptogramin B (MLS) B These antibiotics share the same ribosome binding site and exhibit cross-resistance. Among them, the fourteen-membered macrolide antibiotic erythromycin is a crucial treatment for upper and lower respiratory tract infections. Clinically, it is used to treat infections caused by pathogens such as Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, Moraxella catarrhalis, and Mycoplasma pneumoniae, as well as skin and soft tissue infections. It has mild side effects and has provided a highly effective and safe route of administration for humans, especially children, for half a century. Since the main antibacterial mechanism is the interaction of the hydroxyl and tertiary amino groups of the 5-position glycosamine with hydrogen bonds in the 50S subunit nascent peptide release channel of ribosomal A2058 / A2059, mutations in the A2058 / A2059 bases of bacterial ribosomal ribosomal molecule, or the expression of methyltransferases by strains containing the erm gene leading to N6 methylation of A2058, can cause a sharp decrease in the affinity of erythromycin-type drugs. In addition, strains containing the mef gene can be induced to express efflux pump proteins by erythromycin containing cladinose, resulting in a decrease in intracellular drug molecule concentration below the antibacterial level and drug resistance.
[0003] The second-generation erythromycins that emerged in the 1980s—clarithromycin and azithromycin—while exhibiting high acid resistance and favorable pharmacokinetic properties, lacked antibacterial activity against erythromycin-resistant bacteria. This is primarily because the claridin sugar at the 3-position induces bacterial resistance, leading to the modification of the key target A2058 or its removal from the cell by efflux pumps.
[0004] As a third-generation erythromycin, ketolactone TE802 is active only against efflux-resistant MEF and induced ERM-resistant bacteria, but not against constitutively resistant ERM-resistant bacteria. Telithromycin is the only erythromycin derivative approved to date for the treatment of community-acquired bacterial pneumonia. It exhibits excellent antibacterial activity against induced and efflux-resistant bacteria, and because it targets the A752 and U2609 base pairs of the microbial ribosome, it also shows good antibacterial activity against constitutively resistant Streptococcus pneumoniae and Streptococcus pyogenes. However, telithromycin remains inactive against constitutively resistant Staphylococcus aureus and drug-resistant Mycoplasma. After its market launch, telithromycin was found to have hepatotoxicity, leading to strict restrictions on its use. Other compounds in clinical trials, due to their similar ketolactone structures, faced safety concerns, resulting in halted or terminated development, leaving telithromycin as the only approved ketolactone for the past two decades. Ketolactones in phase III clinical trials, such as solithromycin, have the same antibacterial target as telithromycin, but their marketing applications have been rejected.
[0005] Therefore, the challenge is to find a novel macrolide antibiotic that can treat infections caused by pathogens resistant to erythromycin and telithromycin. Summary of the Invention
[0006] To address the aforementioned technical problems, this invention provides a compound of formula (I), its stereoisomers, tautomers, isotope labels, nitrogen oxides, solvates, polymorphs, metabolites, esters, pharmaceutically acceptable salts, or prodrugs:
[0007]
[0008] Where X represents O or NH;
[0009] A represents O or NR;
[0010] R represents C that can be arbitrarily replaced by one, two, or more R3s. 1-6 Alkyl, -3-10 membered heterocyclic group -C 1-6 Alkyl group, -CH=NO-C 1-6 alkyl;
[0011] Each R3 may be the same or different, and is independently selected from H, halogen, OH, CN, NO2, NH2, COOH, -R4, -R4-R5;
[0012] R4 and R5 represent C 6-10 Aryl or 5-10 heteroaryl, wherein C 6-10 The aryl or 5-10 heteroaryl group can be unsubstituted or substituted with one, two or more of the following groups: halogen, OH, CN, NO2, NH2, COOH;
[0013] Alternatively, when X represents NH, A represents NR, and R is selected from C 1-6 In the case of alkyl groups, C 1-6 The alkyl terminus is connected to X to form a ring;
[0014] Z represents CH2, NH, or O;
[0015] Y represents C 2-6 Alkyne group or 3-10 membered heterocyclic group containing one heteroatom selected from N, O or S;
[0016] D represents CH or N;
[0017] R1 represents C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic groups, C 6-10 Aryl or 5-10 heteroaryl; the C 1-6 Alkyl, C 3-10 Cycloalkyl, 3-10 membered heterocyclic groups, C 6-10 The aryl or 5-10 membered heteroaryl groups can be unsubstituted or substituted with one, two or more of the following groups: halogen, OH, CN, NO2, NH2, COOH;
[0018] R2 represents H, halogen, C 1-6 Alkyl or C 1-6 Alkoxy;
[0019] m is selected from integers from 0 to 10; for example, integers selected from 0 to 8, such as 1, 2, 3, 4 or 5;
[0020] n is an integer selected from 0 to 10, for example, an integer selected from 0 to 6, such as 0, 1, 2 or 3;
[0021] And it has the following condition: when Y represents C 2-6 When it is an alkynyl group, A is not O.
[0022] According to some implementation schemes, A is selected from O or NR, and R is selected from C. 1-6 Alkyl, -C 1-6 Alkyl-NH2, -C 1-6 Alkyl-R4-R5;
[0023] R4 and R5 are selected from C. 6-10 Aryl or 5-10 heteroaryl, wherein at least one heteroatom is selected from N, for example, 1, 2 or 3 heteroatoms are selected from N; for example, phenyl, naphthyl, pyridinyl, imidazolyl, triazole, benzoquinolinyl, diazanaphthyl, thiazolyl, etc.
[0024] According to some implementation schemes, A is selected from NR, and R is selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, -methyl-NH2, -ethyl-NH2, -propyl-NH2, -butyl-NH2, -propyl-imidazolium-pyridine, -butyl-imidazolium-pyridine, -butyl-triazole-pyridine, -butyl-triazole-aminobenzene, -pentyl-imidazolium-pyridine;
[0025] Alternatively, when X represents NH, A represents NR, and R is selected from ethyl, propyl, or butyl, the ethyl, propyl, or butyl end is connected to X to form a ring;
[0026] According to some implementation schemes, A is selected from NR, and R is selected from methyl, ethyl, ethyl-NH2, etc.
[0027] Alternatively, when X represents NH, A represents NR, and R is selected from ethyl, the ethyl terminus is connected to X to form a ring;
[0028] According to some implementation schemes, Z represents CH2 or O;
[0029] According to some implementation schemes, Y represents ethynyl, propynyl, pyrrolidinyl, or piperidinyl;
[0030] According to some implementation schemes, Y represents acetylene group, (like ),
[0031] According to some implementation schemes, R1 represents methyl, ethyl, cyclopropyl, or fluorocyclopropyl;
[0032] According to some implementation schemes, R2 represents H, a halogen, and the halogen is selected, for example, from fluorine, preferably substituted at the 6-position;
[0033] According to some implementation schemes, m is selected from 2, 3, 4 or 5;
[0034] According to some implementation schemes, n is selected from 0, 1, or 2.
[0035] According to some embodiments, the compound shown in formula (I) has the structure shown in formula (I-1):
[0036]
[0037] Where R' represents -C 1-6 Alkyl groups Z, Y, D, R1, R2, m, and n have the definitions described above.
[0038] According to some implementation schemes, R' is selected from -CH2CH2-, -CH2CH2CH2-, -CH(CH3)CH2-, -CH(CH3)CH(CH3)-, -C(CH3)(CH3)CH(CH3)-, -C(CH3)(CH3)CH2-, -C(CH3)(CH3)C(CH3)(CH3)-.
[0039] According to some embodiments, the compound shown in formula (I) has the structure shown in formula (I-2):
[0040]
[0041] Among them, R, Z, Y, D, R1, R2, m, and n have the definitions described above.
[0042] According to an embodiment of the present invention, the compound shown in formula (I) has the structure shown in formula (II).
[0043]
[0044] Among them, X, A, Z, R1, R2, m, and n have the definitions described above.
[0045] According to an embodiment of the present invention, the compound shown in formula (I) has the structure shown in formula (II-1).
[0046]
[0047] Where R' represents -C 1-6 Alkyl groups Z, R1, R2, m, and n have the definitions described above.
[0048] According to an embodiment of the present invention, the compound shown in formula (I) has the structure shown in formula (II-2).
[0049]
[0050] Among them, R, Z, R1, R2, m, and n have the definitions described above.
[0051] According to an embodiment of the present invention, the compound shown in formula (I) has the structure shown in formula (III).
[0052]
[0053] Among them, X, A, Z, R1, R2, m, and n have the definitions described above.
[0054] According to an embodiment of the present invention, the compound shown in formula (I) has the structure shown in formula (III-1).
[0055]
[0056] Among them, R', Z, R1, R2, m, and n have the definitions described above.
[0057] According to an embodiment of the present invention, the compound shown in formula (I) has the structure shown in formula (III-2).
[0058]
[0059] Among them, R, Z, R1, R2, m, and n have the definitions described above.
[0060] According to an embodiment of the present invention, the compound represented by formula (I) is selected from the structures shown below:
[0061]
[0062]
[0063] According to embodiments of the present invention, the pharmaceutically acceptable salt comprises a salt formed by a nitrogen atom on the tertiary amino group or the side chain heterocycle of 5'-deglycosamine and a pharmaceutically acceptable organic or inorganic acid. Preferably, the inorganic acid is hydrochloric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, or phosphoric acid; and the organic acid is acetic acid, malonic acid, methanesulfonic acid, succinic acid, p-toluenesulfonic acid, citric acid, maleic acid, fumaric acid, malic acid, or citric acid.
[0064] According to embodiments of the present invention, the pharmaceutically acceptable salt further includes a salt formed by the carboxyl group in the compound and a pharmaceutically acceptable organic or inorganic base. Preferably, the inorganic base may be one or more of sodium hydroxide, potassium hydroxide, sodium carbonate, bicarbonate, disodium hydrogen phosphate, trisodium phosphate, diammonium hydrogen phosphate, dipotassium hydrogen phosphate, potassium phosphate, sodium metaphosphate, and dilute ammonia solution; and the organic base may be one or more of meglumine, meglumine, meglumine octylamine, tromethamine, anhydrous or hexahydrate piperazine, morpholine, nicotinamide, 1,2-hexamethylenediamine, tris(hydroxymethyl)aminomethane, triethanolamine, diethanolamine, ethanolamine, isopropanolamine, diisopropanolamine, diisopropylamine, diethylamine, ethylenediamine, and benzamide.
[0065] According to an embodiment of the present invention, the prodrug has the structure shown in formula (IV) or formula (V):
[0066]
[0067] Wherein, E represents the following groups that are unsubstituted or optionally substituted by one, two or more Rb groups: C 1-12 Alkyl, C 3-20 Cycloalkyl, 3-20 membered heterocyclic groups, C 6-20Aryl or 5-20 heteroaryl groups; Rb selected from halogens, C 1-12 Alkyl or C 1-12 Alkoxy groups; X, A, Z, Y, D, R1, R2, m, n have the definitions described above.
[0068] The present invention also provides a method for preparing the compound of formula (I), comprising the following steps:
[0069] Intermediate M-1 reacts to give compound M-2, and compound M-2 is further reacted to prepare compound (I);
[0070]
[0071] Wherein, X, A, Z, Y, D, R1, R2, m, and n have the definitions described above, and G represents a hydroxyl protecting group.
[0072] The present invention also provides intermediate compounds represented by formula M-1 or M-2:
[0073]
[0074] Where X, A, Z, Y, m, and n have the definitions described above, and G represents a hydroxyl protecting group.
[0075] According to an embodiment of the present invention, a method for preparing the compound of formula (II) includes the following steps:
[0076] Intermediate M-1 reacts with formula (W) to give compound M-2-1, and compound M-2-1 reacts with formula (V) and then removes the protecting group to prepare compound (II);
[0077]
[0078] Wherein, X, A, Z, m, n, R1, and R2 have the definitions described above, and G represents a hydroxyl protecting group.
[0079] According to an embodiment of the present invention, a method for preparing the compound of formula (III) includes the following steps:
[0080] Intermediate M-1-2 reacts with acetylacetonine hydrochloride to give compound M-2-2, compound M-2-2 reacts with compound (V-2) to prepare the product, and then the protecting group is removed to give compound (III);
[0081]
[0082] Wherein, X, A, Z, m, n, R1, and R2 have the definitions described above, and G represents a hydroxyl protecting group.
[0083] According to embodiments of the present invention, the above preparation method can be carried out in the presence of a solvent. For example, the solvent may be selected from at least one of the following: alcohols, such as methanol, ethanol, isopropanol, n-butanol; ethers, such as ethyl propyl ether, n-butyl ether, anisole, phenethyl ether, cyclohexyl methyl ether, dimethyl ether, diethyl ether, dimethyl ethylene glycol, biphenyl ether, dipropyl ether, diisopropyl ether, di-n-butyl ether, diisobutyl ether, diisopentyl ether, ethylene glycol dimethyl ether, isopropyl ethyl ether, methyl tert-butyl ether, tetrahydrofuran, methyl tetrahydrofuran, dioxane, dichlorodiethyl ether, and cyclohexane. Polyethers of ethylene oxide and / or propylene oxide; aliphatic, cycloaliphatic or aromatic hydrocarbons, such as pentane, hexane, heptane, octane, nonane, and hydrocarbons that may be substituted with fluorine and chlorine atoms, such as methylene chloride, dichloromethane, trichloromethane, carbon tetrachloride, fluorobenzene, chlorobenzene or dichlorobenzene; cyclohexane, methylcyclohexane, petroleum ether, octane, benzene, toluene, bromobenzene, xylene; esters such as methyl acetate, ethyl acetate, butyl acetate, isobutyl acetate and dimethyl carbonate, dibutyl carbonate or ethylene carbonate; acetonitrile.
[0084] The present invention also provides a pharmaceutical composition comprising a compound of formula (I), a stereoisomer thereof, a tautomer thereof, an isotope label thereof, a nitrogen oxide thereof, a solvate thereof, a polymorph thereof, a metabolite thereof, an ester thereof, a pharmaceutically acceptable salt thereof, or a prodrug thereof.
[0085] According to an embodiment of the present invention, the pharmaceutical composition further comprises pharmaceutically acceptable excipients.
[0086] According to embodiments of the present invention, the pharmaceutical composition may further contain one or more additional therapeutic agents.
[0087] The present invention also provides compounds of formula (I), their stereoisomers, tautomers, isotope labels, nitrogen oxides, solvates, polymorphs, metabolites, esters, pharmaceutically acceptable salts or prodrugs, or the use of said pharmaceutical compositions in the preparation of pharmaceuticals, such as in the preparation of antibacterial drugs.
[0088] According to an embodiment of the present invention, the drug is an antimicrobial drug, such as an antibiotic.
[0089] According to an embodiment of the present invention, the antimicrobial drug is used to inhibit or kill at least one of the following pathogenic microorganisms: Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, Staphylococcus aureus, Staphylococcus epidermidis, Moraxella catarrhalis, Mycoplasma, or Chlamydia. According to a specific embodiment of the present invention, the antimicrobial drug is used to inhibit or kill at least one of the following bacterial species that are sensitive to erythromycin or have different drug resistance types: sensitive Streptococcus pneumoniae, constitutively resistant Streptococcus pneumoniae, efflux-resistant Streptococcus pneumoniae, sensitive Staphylococcus aureus, induced resistant Staphylococcus aureus, constitutively resistant Staphylococcus aureus, sensitive Streptococcus pyogenes, efflux-resistant Streptococcus pyogenes, induced resistant Streptococcus pyogenes, constitutively resistant Streptococcus pyogenes, Haemophilus influenzae, and Moraxella catarrhalis.
[0090] The present invention also provides a compound of formula (I) for use against pathogenic microorganisms, its stereoisomers, tautomers, isotope labels, nitrogen oxides, solvates, polymorphs, metabolites, esters, pharmaceutically acceptable salts or prodrugs or said pharmaceutical compositions.
[0091] The present invention also provides the use of the compound of formula (I), its stereoisomers, tautomers, isotopic labels, nitrides, solvates, polymorphs, metabolites, esters, pharmaceutically acceptable salts or prodrugs, or the pharmaceutical composition thereof as an antibiotic.
[0092] The present invention also provides a method for combating pathogenic microorganisms, comprising administering to a patient a therapeutically effective amount of a compound of formula (I), its stereoisomers, tautomers, isotope labels, nitrogen oxides, solvates, polymorphs, metabolites, esters, pharmaceutically acceptable salts or prodrugs, or at least one of the pharmaceutical compositions thereof.
[0093] According to an embodiment of the present invention, the pathogenic microorganism may be at least one of the following: Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, Staphylococcus aureus, Staphylococcus epidermidis, Moraxella catarrhalis, Mycoplasma or Chlamydia.
[0094] In some implementations, the patient is a mammal, preferably a human.
[0095] Beneficial effects
[0096] This article provides compounds of formula (I), their stereoisomers, tautomers, isotopic labels, nitrogen oxides, solvates, polymorphs, metabolites, esters, pharmaceutically acceptable salts or prodrugs, or pharmaceutical compositions thereof, which have good antibacterial and anti-inflammatory effects and can be used as antibiotics to treat infections caused by pathogens resistant to erythromycin and telithromycin.
[0097] The compounds in this invention can also act on both ribosomes and topoisomerases simultaneously.
[0098] Terminology Definitions and Explanations
[0099] Unless otherwise stated, the definitions of groups and terms recorded in this application specification and claims, including definitions as examples, exemplary definitions, preferred definitions, definitions recorded in tables, and definitions of specific compounds in the examples, can be arbitrarily combined and combined with each other. Such combinations and combinations of group definitions and compound structures should be understood as being within the scope of this application specification and / or claims.
[0100] Unless otherwise stated, the numerical ranges described in this specification and claims are equivalent to describing at least each specific integer value therein. For example, the numerical range "0-10" is equivalent to describing each integer value in the numerical range "0-10", namely 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10.
[0101] It should be understood that in this article, when describing one, two or more, "more" should refer to integers greater than 2, such as 3 or greater than or equal to 3, such as 3, 4, 5, 6, 7, 8, 9 or 10.
[0102] Used in the context of this invention Represents a chemical bond.
[0103] Term "C" 1-12 "Alkyl" indicates a straight-chain or branched saturated hydrocarbon group having 1-12 carbon atoms. For example, "C 1-6 "alkyl" refers to a straight-chain or branched saturated hydrocarbon group having 1, 2, 3, 4, 5, or 6 carbon atoms. The C 1-6 Alkyl groups include C 1-3 Alkyl, C 3-6 Alkyl groups, etc. The alkyl group is, for example, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, 2-methylbutyl, 1-methylbutyl, 1-ethylpropyl, 1,2-dimethylpropyl, neopentyl, 1,1-dimethylpropyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 2-ethylbutyl, 1-ethylbutyl, 3,3-dimethylbutyl, 2,2-dimethylbutyl, 1,1-dimethylbutyl, 2,3-dimethylbutyl, 1,3-dimethylbutyl or 1,2-dimethylbutyl, etc., or isomers thereof.
[0104] Term "C" 2-6 "Alkyne" should be understood as referring to a straight-chain or branched hydrocarbon group that contains one or more triple bonds and has 2, 3, 4, 5, or 6 carbon atoms, for example, having 2 or 3 carbon atoms ("C"). 2-3The alkynyl group is, for example, ethynyl, prop-1-alkynyl, prop-2-alkynyl, but-1-alkynyl, but-2-alkynyl, but-3-alkynyl, pent-1-alkynyl, pent-2-alkynyl, pent-3-alkynyl, pent-4-alkynyl, hex-1-alkynyl, hex-2-alkynyl, hex-3-alkynyl, hex-4-alkynyl, hex-5-alkynyl, 1-methylprop-2-alkynyl, 2-methylbut-3-alkynyl, 1-methylbut-3-alkynyl, 1-methylbut-2-alkynyl, 3-methylbut-1-alkynyl, 1-ethylprop-2-alkynyl, 3-methylpent-4-alkynyl, 2-methyl Pentyl-4-ynyl, 1-methylpentyl-4-ynyl, 2-methylpentyl-3-ynyl, 1-methylpentyl-3-ynyl, 4-methylpentyl-2-ynyl, 1-methylpentyl-2-ynyl, 4-methylpentyl-1-ynyl, 3-methylpentyl-1-ynyl, 2-ethylbutyl-3-ynyl, 1-ethylbutyl-3-ynyl, 1-ethylbutyl-2-ynyl, 1-propylpropyl-2-ynyl, 1-isopropylpropyl-2-ynyl, 2,2-dimethylbutyl-3-ynyl, 1,1-dimethylbutyl-3-ynyl, 1,1-dimethylbutyl-2-ynyl, or 3,3-dimethylbutyl-1-ynyl.
[0105] Term "C" 3-20 "Cycloalkyl" should be understood to refer to saturated monocyclic, bicyclic, or bridged cycloalkanes having 3 to 20 carbon atoms, preferably "C". 3-10 "Cycloalkyl". "C" 3-10 "Cycloalkyl" refers to a saturated monovalent monocyclic, bicyclic (e.g., fused, bridged, spirocyclic) hydrocarbon ring or tricyclic alkane having 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms. The C... 3-10 Cycloalkyl groups include C 3-8 cycloalkyl, C 3-5 cycloalkyl, C 6-8 cycloalkyl, C 3-4 cycloalkyl, C 5-6 Cycloalkyl, C6 cycloalkyl, etc. The C... 3-10 Cycloalkyl groups can be monocyclic hydrocarbon groups, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, or cyclodecyl; or bicyclic hydrocarbon groups, such as borneolyl, indolyl, hexahydroindolyl, tetrahydronaphthyl, decahydronaphthyl, bicyclo[2.1.1]hexyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.1]heptenyl, 6,6-dimethylbicyclo[3.1.1]heptyl, 2,6,6-trimethylbicyclo[3.1.1]heptyl, bicyclo[2.2.2]octyl, 2,7-diazaspiro[3,5]nonyl, 2,6-diazaspiro[3,4]octyl; or tricyclic hydrocarbon groups, such as adamantyl.
[0106] The term "3-20 membered heterocyclic group" should be understood to refer to a saturated monocyclic, bicyclic, or bridged cyclic alkane comprising 1-5 heteroatoms independently selected from N, O, and S, forming a non-aromatic cyclic group with a total ring atom number of 3-20 (e.g., 3, 4, 5, 6, 7, 8, 9, 10, etc.), preferably "3-10 membered heterocyclic group". The term "3-10 membered heterocyclic group" means a saturated or unsaturated non-aromatic ring or ring system containing at least one heteroatom selected from O, S, and N. The heterocyclic group can be connected to the rest of the molecule via any one of the carbon atoms or a nitrogen atom (if present). The heterocyclic group can include fused or bridged rings and spirocyclic rings. Specifically, the heterocyclic group may include, but is not limited to: 3-membered rings, such as azirropropyl and oxacyclopropyl; 4-membered rings, such as azirrobutyl and oxacyclobutyl; 5-membered rings, such as tetrahydrofuranyl, dioxacyclopentenyl, pyrrolyl, imidazoalkyl, pyrazolyl, or pyrrololinyl; or 6-membered rings, such as tetrahydropyranyl, piperidinyl, morpholinyl, dithiaalkyl, thiomorpholinyl, piperazinyl, or trithiaalkyl; or 7-membered rings, such as diazacycloheptyl. Optionally, the heterocyclic group may be benzofused. The heterocyclic group may be bicyclic, for example, but not limited to, 5,5-membered rings, such as hexahydrocyclopenta[c]pyrrolo-2(1H)-yl rings, or 5,6-membered bicyclic rings, such as hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl rings. The heterocyclic group can be partially unsaturated, meaning it can contain one or more double bonds, such as, but not limited to, dihydrofuranyl, dihydropyranyl, 2,5-dihydro-1H-pyrroleyl, 4H-[1,3,4]thiadiazinyl, 1,2,3,5-tetrahydrooxazolyl, or 4H-[1,4]thiazinyl. Alternatively, it can be benzofused, such as, but not limited to, dihydroisoquinolinyl. When the 3-10 membered heterocyclic group is linked to other groups to form the compounds of the present invention, the carbon atom on the 3-10 membered heterocyclic group can be linked to other groups, or a heterocyclic atom (such as a nitrogen atom) on the ring of the 3-10 membered heterocyclic group can be linked to other groups. For example, when the 3-10 membered heterocyclic group is selected from piperazineyl or tetrahydropyrroleyl, the nitrogen atom or carbon atom on the piperazineyl group can be linked to other groups. Alternatively, when the 3-10 membered heterocyclic group is selected from piperidinyl, it can be the nitrogen atom on the piperidinyl ring or the carbon atom at the ortho, meta or para position connected to other groups.
[0107] Term "C" 6-20 "Aryl" should be understood as referring to a monocyclic, bicyclic, or tricyclic hydrocarbon ring with 6-20 carbon atoms, indicating aromaticity or partial aromaticity. The term "C"... 6-10"Aryl" should be understood to preferably represent a monovalent aromatic or partially aromatic monocyclic, bicyclic, or tricyclic hydrocarbon ring having 6, 7, 8, 9, or 10 carbon atoms, particularly a ring having 6 carbon atoms ("C6 aryl"), such as phenyl; or biphenyl, or a ring having 9 carbon atoms ("C9 aryl"), such as indenyl or indenyl, or a ring having 10 carbon atoms ("C9 aryl"). 10 Aryl), such as tetrahydronaphthyl, dihydronaphthyl, or naphthyl. When the C 6-10 When the aryl group is substituted, it can be monosubstituted or polysubstituted. Furthermore, there are no restrictions on the substitution site; for example, it can be ortho, para, or meta substituted.
[0108] The term "5-20-membered heteroaryl" should be understood to include monocyclic, bicyclic, or tricyclic aromatic ring systems, including aromatic or partially aromatic ones, having 5-20 ring atoms and containing 1-5 heteroatoms independently selected from N, O, and S, such as "5-14-membered heteroaryl". The term "5-10-membered heteroaryl" refers to a monovalent or polyvalent monocyclic, bicyclic, or tricyclic aromatic ring system having 5, 6, 7, 8, 9, or 10 ring atoms, with its ring atoms containing 1-5 heteroatoms independently selected from N, O, and S. The bicyclic and tricyclic aromatic ring systems can be fused rings, spirocyclic, or bridged rings. The 5-10-membered heteroaryl contains 1-5 heteroatoms, preferably 1-3. Additionally, in each case, the 5-10-membered heteroaryl can be benzofused. The 5-10 membered heteroaryl groups include 5-8 membered heteroaryl groups, 5-9 membered heteroaryl groups, 5-10 membered heteroaryl groups, 5-6 membered heteroaryl groups, 8-10 membered heteroaryl groups, and 6 membered heteroaryl groups. Examples of heteroaryl groups include, but are not limited to: 5-membered rings, such as oxazolyl, pyrazolyl, thiophene, thiazolyl, triazole, imidazolyl, etc.; and 6-membered rings, such as pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, etc. The heterocyclic group can be bicyclic, including but not limited to: 5,5-membered rings, such as tetrahydrocyclopentanopyrazole; 5,6-membered rings, such as tetrahydroindole, tetrahydropyrazolopyridine, tetrahydroimidazopyridine, tetrahydrobenzisoxazole, tetrahydrobenzisoxazole, tetrahydrobenzothiazole, tetrahydrobenzisoxiazole, dihydrofuranopyrazole, tetrahydrobenzofuran, dihydrobenzofuran, tetrahydrobenzothiophene; 6,6-membered rings, such as tetrahydroquinoline; 5,7-membered rings, such as tetrahydrocycloheptanthiazole, tetrahydrocycloheptanfuran. The heterocyclic group can be tricyclic, including but not limited to: 6,7-dihydrospiro[cyclopropane-1,5-pyrrolo[1,2-c]imidazole]. When the 5-10-membered heteroaryl groups are substituted, they can be monosubstituted or polysubstituted. Furthermore, there are no restrictions on the substitution sites; for example, hydrogen atoms bonded to carbon atoms on the heteroaryl ring can be substituted, or hydrogen atoms bonded to heteroatoms on the heteroaryl ring can be substituted.
[0109] The term "spirocycle" refers to a ring system in which two rings share a single ring atom.
[0110] The term "fused ring" refers to a ring system in which two rings share two cyclic atoms.
[0111] The term "bridged ring" refers to a ring system in which two rings share three or more cyclic atoms.
[0112] The term "halogen" refers to fluorine, chlorine, bromine, or iodine.
[0113] Crystallization often produces solvates of the compounds of the present invention. As used herein, a solvate is a combination of one or more molecules of the compounds of the present invention and one or more solvent molecules.
[0114] The solvent can be water, in which case the solvate is a hydrate. Alternatively, it can be an organic solvent. Therefore, the compounds of this invention can exist as hydrates, including monohydrates, dihydrates, hemihydrates, trihydrates, tetrahydrates, etc., and the corresponding solvated forms. The compounds of this invention can be true solvates, but in other cases, they may simply retain water or a mixture of water and some other solvents by chance. The compounds of this invention can react in a solvent or precipitate or crystallize in a solvent. The solvates of the compounds of this invention are also included within the scope of this invention.
[0115] As used herein, the term “acceptable” in relation to formulations, compositions or ingredients means that it does not have a lasting harmful effect on the overall health of the subject of treatment.
[0116] As used herein, the term "pharmaceutically acceptable" means a substance (such as a carrier or diluent) that does not affect the biological activity or properties of the compounds of the present invention and is relatively non-toxic, i.e., that the substance can be administered to an individual without causing an adverse biological reaction or interacting adversely with any component contained in the composition.
[0117] Those skilled in the art will understand that the compounds of the present invention can exist in the form of various pharmaceutically acceptable salts. If these compounds have a basic center, they can form acid addition salts; if these compounds have an acidic center, they can form base addition salts; if these compounds contain both an acidic center (e.g., a carboxyl group) and a basic center (e.g., an amino group), they can also form internal salts.
[0118] The term "tautomer" refers to a functional group isomer resulting from the rapid movement of an atom between two positions within a molecule. The compounds of this invention can exhibit tautomerism. Tautomers can exist in two or more interconvertible forms. Proton-transfer tautomers arise from the migration of covalently bonded hydrogen atoms between two atoms. Tautomers generally exist in equilibrium form; attempts to isolate a single tautomer typically yield a mixture whose physicochemical properties are consistent with those of the mixture of compounds. The equilibrium position depends on the intramolecular chemical characteristics. For example, in many aliphatic aldehydes and ketones such as acetaldehyde, the ketone form is dominant; while in phenols, the enol form is dominant. This invention encompasses all tautomeric forms of the compounds.
[0119] Depending on their molecular structure, the compounds of the present invention can be chiral, and therefore may exist in various enantiomeric forms. Thus, these compounds can exist in racemic or optically active forms. The compounds of the present invention encompass isomers of each chiral carbon in the R or S configuration, or mixtures thereof, and racemates. The compounds of the present invention or their intermediates can be isolated as enantiomeric compounds by chemical or physical methods known to those skilled in the art, or used in this form for synthesis. In the case of racemic amines, diastereomers are obtained from the mixture by reaction with an optically active resolving agent. Examples of suitable resolving agents are optically active acids, such as tartaric acid in both R and S forms, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid, suitable N-protected amino acids (e.g., N-benzoylproline or N-benzenesulfonylproline), or various optically active camphorsulfonic acids. Chromatographic enantiomeric separation can also be advantageously performed using optically active resolving agents (e.g., dinitrobenzoylphenylglycine immobilized on silica gel, cellulose triacetate or other carbohydrate derivatives, or chiral derivatized isobutylene ester polymers). Suitable eluents for this purpose are aqueous or alcoholic solvent mixtures, such as hexane / isopropanol / acetonitrile.
[0120] In this application, "pharmaceutical composition" refers to a formulation of the compounds of the present invention with a medium generally accepted in the art for delivering bioactive compounds to mammals (e.g., humans). This medium includes pharmaceutically acceptable carriers. The purpose of the pharmaceutical composition is to facilitate administration to the organism, thereby promoting the absorption of the active ingredient and the exertion of its bioactivity.
[0121] In this application, "pharmaceuticalally acceptable excipients" include, but are not limited to, any adjuvants, carriers, excipients, flow aids, sweeteners, diluents, preservatives, dyes / colorants, flavoring agents, surfactants, wetting agents, dispersants, suspending agents, stabilizers, isotonic agents, solvents, or emulsifiers that are permitted by the relevant government regulatory authorities to be acceptable for human or livestock use.
[0122] In this application, the term "solvent" refers to a compound of the present invention or a salt thereof comprising a stoichiometric or non-stoichiometric solvent bound by intermolecular noncovalent forces, and a hydrate when the solvent is water.
[0123] In this application, the term "prodrug" refers to a compound of the present invention that can be converted into a biologically active form under physiological conditions or by solvation. The prodrugs of the present invention are prepared by modifying functional groups in the compound; such modification can be performed conventionally or removed in vivo to obtain the parent compound. Prodrugs comprise compounds formed by attaching a hydroxyl or amino group to any group within the compound of the present invention. When a prodrug of the compound of the present invention is administered to a mammalian individual, the prodrug is cleaved to form free hydroxyl and free amino groups, respectively.
[0124] "Isotope" refers to all isotopes of atoms appearing in the compounds of this invention. Isotopes include those atoms having the same atomic number but different mass numbers. Examples of isotopes suitable for inclusion in the compounds of this invention are hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, and chlorine, respectively, for example, but not limited to, [examples of isotopes]. 2 H, 3 H, 13 C 14 C 15 N、 18 O、 31 P, 32 P, 35 S, 18 F and 36 C1. The isotope-labeled compounds of the present invention can generally be prepared by conventional techniques known to those skilled in the art or by methods similar to those described in the appended examples, using suitable isotope-labeled reagents instead of non-isotope-labeled preparations. Such compounds have a variety of potential uses, for example, as standards and reagents in the determination of biological activity. In the case of stable isotopes, such compounds have the potential to advantageously alter biological, pharmacological, or pharmacokinetic properties.
[0125] The term "treatment" and other similar synonyms used in this article include the following meanings:
[0126] (i) To prevent the occurrence of disease or condition in mammals, especially when such mammals are susceptible to the disease or condition but have not yet been diagnosed with it;
[0127] (ii) To suppress a disease or symptom, that is, to curb its development;
[0128] (iii) To alleviate a disease or symptom, that is, to cause the condition of the disease or symptom to subside; or
[0129] (iv) To alleviate the symptoms caused by the disease or condition.
[0130] The term "patient" refers to any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, pigs, cattle, sheep, horses, or primates, with humans being the most preferred.
[0131] The term “therapeutic effective amount” refers to the amount of an active compound or drug that researchers, veterinarians, physicians, or other clinicians are searching for in tissues, systems, animals, individuals, or humans to elicit a biological or medical response. It includes one or more of the following: (1) prevention of disease: e.g., prevention of disease, disorder, or condition in individuals susceptible to disease, disorder, or symptom but not yet experiencing or exhibiting the pathology or symptoms of the disease; (2) suppression of disease: e.g., suppression of disease, disorder, or symptom in individuals experiencing or exhibiting the pathology or symptoms of the disease, disorder, or symptom (i.e., prevention of further development of the pathology and / or symptoms); (3) relief of disease: e.g., relief of disease, disorder, or symptom in individuals experiencing or exhibiting the pathology or symptoms of the disease, disorder, or symptom (i.e., reversal of the pathology and / or symptoms). Detailed Implementation
[0132] The technical solution of the present invention will be further described in detail below with reference to specific embodiments. It should be understood that the following embodiments are merely illustrative and explanatory of the present invention, and should not be construed as limiting the scope of protection of the present invention. All technologies implemented based on the above content of the present invention are covered within the scope of protection intended by the present invention.
[0133] Unless otherwise stated, the raw materials and reagents used in the following examples are commercially available products or can be prepared by known methods.
[0134] The side chain and aryl structure used in this article:
[0135]
[0136] The following example illustrates the preparation process of compounds 1-36 of the present invention, with the reaction formula as follows:
[0137]
[0138] Reaction conditions and reagents: a. Benzoic anhydride, DMAP (4-dimethylaminopyridine), THF, N,N-dimethylethylenediamine, room temperature; b. CDI (carbonyl diimidazole), NaHMDS, THF / DMF = 1.5 / 1, room temperature; c. Different amines (ethylenediamine, 40% methylamine aqueous solution, or ethylamine), acetonitrile, room temperature; or when using telithromycin side chain reagent W3, telithromycin side chain reagent W3, DBU, THF / DMF = 1.5 / 1, 50℃; d. When ethylenediamine is used in step c, the conditions are: acetic acid, ethanol 60℃ followed by 4M HCl solution, ethanol, 45℃; or benzyloxyformyl chloride (CbzCl), triethylamine, dichloromethane followed by 4M HCl solution, ethanol, 45℃; when methylamine, ethylamine, or telithromycin side chain reagent W3 is used in step c, 4M HCl solution is used. HCl solution, ethanol, 45℃; e. CDI, DMAP, dichloromethane, room temperature; f. Side chain (side chain W1 or side chain W2), DBU, DMF, room temperature; g. 12M hydrochloric acid solution, ethanol; h. Compound V1, acetonitrile, 75℃; i. When using feedstock 27-29, 31, the operating conditions are: 1) ethanol, 2N NaOH, room temperature; 2) methanol reflux; when using feedstock 30, the operating conditions are: 1) ethanol, 2N NaOH, room temperature; 2) methanol reflux; 3) Pd / C, methanol, room temperature.
[0139] Preparation Example 1: Synthesis of Compound 1
[0140]
[0141] Clarithromycin (20.00 g, 26.74 mmol), DMAP (3.27 g, 26.74 mmol), and benzoic anhydride (18.15 g, 80.22 mmol) were dissolved in 150 mL of anhydrous tetrahydrofuran. Triethylamine (11.12 mL, 80.22 mmol) was added, and the mixture was stirred at room temperature. The reaction was monitored by TLC. After approximately 48 h of complete reaction, N,N-dimethylethylenediamine (5.84 mL, 53.48 mmol) was added dropwise under ice bath. After reacting for half an hour, the reaction solution was concentrated by rotary evaporation. Then, 200 mL of dichloromethane was added to the system, and the organic phase was washed with saturated ammonium chloride solution, saturated sodium bicarbonate solution, water, and saturated brine, respectively. After the organic phase was evaporated to dryness, anhydrous ethanol was added, and recrystallization yielded 22.44 g (23.47 mmol, 87.8%) of white crystals of compound 1.
[0142] Preparation Example 2: Synthesis of Compound 2
[0143]
[0144] Compound 1 (10.00 g, 10.46 mmol) and CDI (6.78 g, 41.83 mmol) were dispersed in a mixed solution of THF / DMF (42 mL / 15 mL). While stirring, 2 mol / L NaHMDS solution (8.37 mL, 16.73 mmol) was slowly added dropwise. After the addition was complete, the mixture was stirred at room temperature for approximately 2 hours. After the reaction was complete, 100 mL of ethyl acetate was added, followed by washing with saturated sodium bicarbonate solution, water, and saturated saline solution, respectively.
[0145] Drying the organic phase yielded 10.66 g (10.33 mmol, 98.8%) of compound 2 as a white solid.
[0146] Preparation Example 3: General Synthetic Methods for Compounds 3-5
[0147] Compound 2 was dissolved in acetonitrile, and an amine (ethylenediamine, 40% aqueous methylamine, or ethylamine) (10-20 eq) was added at room temperature and stirred for 4-8 h. After the reaction was complete, ethyl acetate was added, followed by washing with water, saturated sodium bicarbonate, and saturated sodium chloride, respectively. The organic phase was then evaporated to dryness to obtain the target compounds 3-5.
[0148] Synthesis of Compound 3
[0149]
[0150] Using compound 2 (8.00 g, 7.75 mmol) and ethylenediamine (5.18 mL, 77.50 mmol) as starting materials, compound 3 (5.27 g, 5.14 mmol, 66.3%) was obtained by following the general synthetic method of this preparation example.
[0151] Synthesis of Compound 4
[0152]
[0153] Compound 4 (19.36 g, 19.47 mmol, 76.0%) was obtained using compound 2 (26.44 g, 25.62 mmol) and 40% aqueous methylamine (20 mL, 256.19 mmol) as raw materials, following the general synthetic method of this preparation example.
[0154] Synthesis of Compound 5
[0155]
[0156] Compound 5 (5.25 g, 5.21 mmol, 53.7%) was obtained using compound 2 (10.00 g, 9.69 mmol) and ethylamine (7 mL, 96.88 mmol) as starting materials, following the general synthetic method of this preparation example.
[0157] Preparation Example 4: Synthesis of Compound 6
[0158]
[0159] Compound 2 (3.85 g, 3.73 mmol) and telithromycin side-chain reagent W3 (0.80 g, 3.69 mmol) were dissolved in DMF / THF, and DBU (0.52 mL, 3.73 mmol) was added. The mixture was reacted at 50 °C for 8 h. After the reaction was completed, ethyl acetate was added, and the mixture was washed with water, saturated sodium bicarbonate and saturated sodium chloride, respectively. The organic phase was then evaporated to dryness to give compound 6 (3.60 g, 3.05 mmol, 81.7%).
[0160] Preparation Example 5: Synthesis of Compound 7
[0161]
[0162] Compound 3 (5.27 g, 5.14 mmol) was dissolved in ethanol (50 mL), and acetic acid (0.55 mL, 9.77 mmol) was added. After the reaction was complete, 2 M hydrochloric acid solution was added, and the mixture was stirred in an oil bath at 40 °C for 2 h. After the reaction was complete, water and methyl tert-butyl ether were added. Ethyl acetate was added to the aqueous layer, and the pH was adjusted to 10. The ethyl acetate layer was washed with water and saturated brine, respectively. The organic layer was evaporated to dryness and purified by column chromatography (100-200 mesh silica gel, developing solvent: dichloromethane:ethanol:ammonia = 10 / 0.2 / 0.1) to give target compound 7 (3.14 g, 4.72 mmol, 91.8%). HRMS (ESI) (M+H) + m / z 744.4409, calcd for C 40 H 62 N3O 10 744.4430. 1H NMR(CDCl3,400MHz)δ:8.10-8.04(m,2H,2H-Bz),7.60-7.53(m,1H,H-Bz),7.49-7.41(m,2H,2H -Bz),5.09-4.99(m,2H,H-13,H-2′),4.72(d,J=7.5Hz,1H,H-1′),3.97(dt,J=2.8Hz,14.3Hz,1 H,CH2),3.85-3.69(m,3H,H-5,CH2),3.66(s,1H,H-11),3.61-3.52(m,1H,H-5′),3.46(dd,J=6 .6Hz,10.6Hz,1H,H-3),3.01-2.94(s,4H,6-O-CH3,CH2),2.94-2.84(m,1H,H-3′),2.71-2.55(m ,3H,H-10,H-2,H-8),2.28(s,6H,-N(CH3)2),1.97-1.84(m,2H,H-4,H-14eq),1.84(d,J=6.7Hz ,1H,3-OH),1.84-1.73(m,1H,H-4′a),1.52-1.29(m,10H,H-7a,H-7b,H-14ax,H-4′b,12-CH3,6 -CH3),1.27(d,J=6.1Hz,3H,5′-CH3),1.23(d,J=6.7Hz,3H,2-CH3),1.16(d,J=6.8Hz,3H,10-C H3),0.98(d,J=7.1Hz,3H,8-CH3),0.80(t,J=7.4Hz,3H,15-CH3),0.70(d,J=7.5Hz,3H,4-CH3). 13 C NMR(CDCl3,100MHz)δ:181.27,175.35,165.33,156.39,132.68,130.74,1 29.77,128.25,99.98,81.90,80.37,78.76,77.67,75.47,72.12,69.03,6 3.36,60.23,49.44,49.24,44.20,43.41,42.62,40.85,37.88,36.55,36. 21,32.02,21.99,21.19,19.68,19.37,15.34,12.65,11.05,10.21,7.74.
[0163] Preparation Example 6: General Synthetic Method for Compounds 8-11
[0164] Compounds 4-6 were dissolved in ethanol (40 mL), and 2 M hydrochloric acid solution (40 mL) was added. The mixture was stirred in an oil bath at 40 °C for 2 h. After the reaction was complete, water and methyl tert-butyl ether were added. Ethyl acetate was added to the aqueous layer and the pH was adjusted to 10. The ethyl acetate layer was washed with water and saturated brine, respectively. The organic layer was evaporated to dryness and then subjected to column chromatography to obtain the target compounds 8-11.
[0165] Synthesis of Compound 8
[0166]
[0167] Using compound 4 (19.36 g, 19.47 mmol) as the starting material, compound 8 (12.89 g, 17.59 mmol, 90.3%) was prepared according to the general synthetic method of this preparation example. The product was purified by column chromatography (100-200 mesh silica gel, developing solvent: dichloromethane: ethanol: ammonia = 10 / 0.2 / 0.1) to obtain compound 8. + m / z 733.4238, calcd for C 39 H 61 N2O 11 733.4270. 1H NMR(CDCl3,400MHz)δ:8.10-8.03(m,2H,2H-Bz),7.61-7.53(m,1H,H-Bz),7.49-7.41(m,2H,2H-Bz) ,5.04(dd,J=7.6Hz,10.5Hz,1H,H-2′),4.99(dd,J=2.4Hz,11.0Hz,1H,H-13),4.75(d,J=7.6Hz,1H, H-1′),3.75(d,J=2.7Hz,1H,H-5),3.63-3.51(m,2H,H-11,H-5′),3.42(dd,J=6.5Hz,10.6Hz,1H,H- 3),3.06(s,3H,CH3),2.93(s,3H,6-O-CH3),2.92-2.84(m,2H,H-3′,H-10),2.66-2.57(m,1H,H-2), 2.56-2.47(m,1H,H-8),2.27(s,6H,-N(CH3)2),2.03-1.83(m,3H,3-OH,H-4,H-14eq),1.83-1.74(m ,1H,H-4′a),1.58-1.49(m,1H,H-7a),1.49-1.35(m,3H,H-7b,H-14ax,H-4′a),1.34-1.28(m,6H,12 -CH3,6-CH3),1.27(d,J=6.1Hz,3H,5′-CH3),1.22(d,J=6.8Hz,3H,2-CH3),1.07(d,J=7.11Hz,3H,8 -CH3), 1.01 (d, J=6.7Hz, 3H, 10-CH3), 0.79 (t, J=7.3Hz, 3H, 15-CH3), 0.71 (d, J=7.5Hz, 3H, 4-CH3).
[0168] Synthesis of Compound 9
[0169]
[0170] Using compound 5 (5.25 g, 5.21 mmol) as the starting material, compound 9 was prepared according to the general synthetic method of this preparation example. The product was purified by column chromatography (100-200 mesh silica gel, developing solvent: dichloromethane: ethanol: ammonia = 10 / 0.2 / 0.1) to give compound 9 (3.62 g, 4.84 mmol, 92.9%). HRMS (ESI) (M+H) + m / z 747.4393, calcd for C 40 H 63 N2O 11 747.4426. 1H NMR(CDCl3,400MHz)δ:8.14-8.01(m,2H,2H-Bz),7.61-7.51(m,1H,H-Bz),7.50-7.40(m ,2H,2H-Bz),5.09-4.95(m,2H,H-13,H-2′),4.75(d,J=7.6Hz,1H,H-1′),3.77(d,J=2.7H z,1H,H-5),3.71-3.46(m,4H,H-11,H-5′,CH2),3.41(dd,J=6.1Hz,10.6Hz,1H,H-3),3.0 1-2.83(m,5H,H-3′,6-O-CH3,H-10),2.68-2.56(m,1H,H-2),2.57-2.47(m,1H,H-8),2.2 8(s,6H,-N(CH3)2),2.01(s,1H,3-OH),1.97-1.82(m,2H,H-4,H-14eq),1.83-1.72(m,1H ,H-4′a),1.62-1.50(m,1H,H-7a),1.50-1.36(m,3H,H-7b,H-14ax,H-4′a),1.32(s,9H,1 2-CH3,6-CH3,5′-CH3),1.24-1.15(m,6H,CH3,2-CH3),1.07(d,J=7.1Hz,3H,8-CH3),1.0 0(d,J=6.7Hz,3H,10-CH3),0.79(t,J=7.2Hz,3H,15-CH3),0.72(d,J=7.4Hz,3H,4-CH3).
[0171] Synthesis of Compound 10
[0172]
[0173] Compound 3 (8.42 g, 8.22 mmol) was dissolved in dichloromethane, and Cb2Cl (1.2 mL, 9.04 mmol) was added. The mixture was stirred at room temperature for 2 h. After the reaction was complete, the organic phase was washed with water, saturated sodium bicarbonate, and saturated brine, respectively. The organic phase was then evaporated to dryness to obtain the intermediate. The intermediate was purified by removing the sugar at the 3-position using the general synthetic method of this preparation example, followed by column chromatography purification (100-200 mesh silica gel, developing solvent: dichloromethane: ethanol: ammonia = 10 / 0.2 / 0.1) to obtain compound 10 (3.73 g, 4.16 mmol, 50.6%). HRMS (ESI) (M+H) + m / z 896.4915, calcd for C 48 H 70 N3O 13 896.4903.1 H NMR(CDCl3,400MHz)δ:8.10-8.02(m,2H,2H-Bz),7.60-7.52(m,1H,H-Bz),7.48-7.42(m,2H,2H-Bz ),7.37-7.27(m,5H,Bn),5.79(t,J=5.4Hz,1H,NH),5.16-4.96(m,4H,CH2,H-13,H-2′),4.71(d,J= 7.6Hz,1H,H-1′),3.96-3.83(m,1H,CH2),3.74(d,J=3.0Hz,1H,H-5),3.71-3.61(m,1H,CH2),3.61 -3.50(m,3H,H-11,CH2),3.48(dd,J=6.5Hz,10.6Hz,1H,H-3),3.33-3.22(m,1H,H-5′),2.93(s,3H ,6-O-CH3),2.91-2.83(m,1H,H-3′),2.65-2.57(m,1H,H-2),2.56-2.46(m,1H,H-8),2.29(s,6H,- N(CH3)2),1.95-1.82(m,4H,H-4,H-14eq,3-OH,H-4′a),1.59-1.35(m,4H,H-7a,H-7b,H-14ax,H-4 ′b),1.34-1.29(m,6H,12-CH3,6-CH3),1.28(d,J=6.2Hz,3H,5′-CH3),1.22(d,J=6.7Hz,3H,2-CH3 ),1.07(d,J=7.2Hz,3H,8-CH3),0.99(d,J=6.8Hz,3H,10-CH3),0.75-0.64(m,6H,15-CH3,4-CH3).
[0174] Synthesis of Compound 11
[0175]
[0176] Using compound 6 (3.60 g, 3.05 mmol) as the starting material, compound 11 (2.05 g, 2.23 mmol, 73.1%) was prepared according to the general synthetic method of this preparation example. The product was purified by column chromatography (100-200 mesh silica gel, developing solvent: dichloromethane: ethanol: ammonia = 10 / 0.2 / 0.1) to obtain compound 11 (2.05 g, 2.23 mmol, 73.1%).
[0177] Preparation Example 7: General Synthetic Method for Compounds 12-16
[0178] Compound 7-11 (1 eq), DMAP (2 eq), and CDI (3 eq) were added to a round-bottom flask, followed by anhydrous dichloromethane. The mixture was reacted at room temperature for 12 h. After the reaction was completed by TLC monitoring, dichloromethane was added, and the mixture was washed successively with saturated ammonium chloride, saturated sodium bicarbonate, water, and saturated brine. The organic phase was then evaporated to dryness to obtain a white solid of the target compound 12-16.
[0179] Synthesis of Compound 12
[0180]
[0181] Using compound 7 (3.14 g, 4.72 mmol) as a starting material, compound 12 (3.06 g, 3.65 mmol, 77.3%) was obtained by following the general synthetic method of this preparation example.
[0182] Synthesis of Compound 13
[0183]
[0184] Using compound 8 (12.89 g, 17.59 mmol) as a starting material, compound 13 (13.80 g, 15.05 mmol, 85.6%) was obtained by following the general synthetic method of this preparation example.
[0185] Synthesis of Compound 14
[0186]
[0187] Using compound 9 (3.62 g, 4.84 mmol) as a starting material, compound 14 (3.85 g, 4.13 mmol, 85.3%) was obtained by following the general synthetic method of this preparation example.
[0188] Synthesis of Compound 15
[0189]
[0190] Using compound 10 (3.73 g, 4.16 mmol) as a starting material, compound 15 (3.20 g, 3.23 mmol, 77.6%) was obtained by following the general synthetic method of this preparation example.
[0191] Synthesis of Compound 16
[0192]
[0193] Using compound 11 (2.05 g, 2.23 mmol) as a starting material, compound 16 (2.10 g, 1.90 mmol, 85.2%) was obtained by following the general synthetic method of this preparation example.
[0194] Preparation Example 8: General Synthetic Methods for Compounds 17-21 and 27-31
[0195] Compound 12-16 (1 eq) was dissolved in DMF, and side chains (W1 or W2) (1.3-1.5 eq) and DBU (1 eq) were added dropwise at room temperature. The reaction was carried out at room temperature for 12 h. The reaction progress was monitored by TLC. After the reaction was complete, ethyl acetate was added, and the organic layer was washed three times with water and once with saturated brine. The organic phase was evaporated to dryness to obtain the intermediate. The intermediate was dissolved in 4 mL of ethanol, and then 2 mL of 12 M HCl was added. The mixture was stirred at room temperature for 2 h. After the reaction was complete, dichloromethane was added, and the pH was adjusted to 10 with ammonia. The organic phase was washed with water, saturated sodium bicarbonate, and saturated brine, respectively. The organic phase was evaporated to dryness to obtain the crude product. The crude product was purified by column chromatography or recrystallization to obtain the compound.
[0196] Synthesis of Compound 17
[0197]
[0198] Compound 17 was prepared using compound 12 (1.50 g, 1.79 mmol) and side chain W1 (0.77 g, 2.68 mmol) as starting materials, following the general synthetic method of this preparation example. The product was recrystallized from ethyl acetate to give compound 17 (1.03 g, 1.11 mmol, 62.0%). HRMS(ESI)(M+H) + m / z 928.5629, calcd for C 49 H 78 FN5O 12 928.5641. 11H NMR (CDCl3, 400 MHz) δ: 8.09 - 7.96 (m, 2H, 2H - Bz), 7.63 - 7.53 (m, 1H, H - Bz), 7.49 - 7.40 (m, 2H, 2H - Bz), 5.45 (t, J = 5.5 Hz, 1H, CONH), 5.05 (dd, J = 2.2 Hz, 10.9 Hz, 1H, H - 13), 5.00 (dd, J = 7.6 Hz, 10.5 Hz, 1H, H - 2′), 4.88 (d, J = 11.1 Hz, 1H, H - 3), 4.30 (d, J = 7.5 Hz, 1H, H - 1′), 4.01 - 3.91 (m, 1H, CH2), 3.86 (d, J = 3.4 Hz, 1H, H - 5), 3.82 - 3.69 (m, 2H, CH2, O - CH), 3.66 (s, 1H, H - 11), 3.66 - 3.56 (m, 2H, O - CH2), 3.51 - 3.34 (m, 3H, 3 - O - CO - NH - CH2, CH2, H - 5′), 3.33 - 3.22 (m, 1H, 3 - O - CO - NH - CH2), 3.15 - 3.09 (m, 2H, -N-(CH2 - CH2)2), 3.07 (s, 3H, 6 - O - CH3), 3.03 - 2.93 (m, 1H, CH2), 2.90 - 2.79 (m, 1H, H - 3′), 2.79 - 2.70 (m, 1H, H - 2), 2.70 - 2.55 (m, 4H, H - 10, H - 8, -N-(CH2 - CH2)2), 2.28 (s, 6H, -N(CH3)2), 2.01 - 1.90 (m, 3H, H - 4, CH2), 1.91 - 1.79 (m, 3H, -N-(CH2 - CH2)2, H - 14ax), 1.79 - 1.69 (m, 1H, H - 4′a), 1.54 - 1.38 (m, 4H, H - 7b, H - 7a, H - 14eq, H - 4′b), 1.36 - 1.29 (m, 8H, 12 - CH3, -N-(CH2 - CH2)2, 6 - CH3), 1.27 (d, J = 6.1 Hz, 3H, 5′ - CH3), 1.15 (d, J = 6.8 Hz, 3H, 2 - CH3,), 1.11 (d, J = 6.8 Hz, 3H, 10 - CH3), 0.99 (d, J = 7.1 Hz, 3H, 8 - CH3), 0.80 (t, J = 7.3 Hz, 3H, 15 - CH3), 0.74 (d, J = 7.5 Hz, 3H, 4 - CH3).
[0199] Synthesis of Compound 27
[0200]
[0201] Compound 27 was prepared using compound 12 (1.56 g, 1.86 mmol) and side chain W2 (0.69 g, 2.43 mmol) as starting materials, following the general synthetic method of this preparation example. The product was recrystallized from ethyl acetate to give compound 27 (1.05 g, 1.13 mmol, 60.7%). HRMS(ESI)(M+H) + m / z 928.5610, calcd for C 49 H 78 FN5O 12 928.5641. 11H NMR (CDCl3, 400 MHz) δ: 8.09 - 8.00 (m, 2H, 2H - Bz), 7.62 - 7.54 (m, 1H, H - Bz), 7.50 - 7.41 (m, 2H, 2H - Bz), 5.45 (t, J = 5.6 Hz, 1H, CONH), 5.05 (dd, J = 2.2 Hz, 11.0 Hz, 1H, H - 13), 5.00 (dd, J = 8.3 Hz, 11.2 Hz, 1H, H - 2′), 4.88 (d, J = 11.0 Hz, 1H, H - 3), 4.30 (d, J = 7.5 Hz, 1H, H - 1′), 4.01 - 3.91 (m, 1H, CH2), 3.86 (d, J = 3.4 Hz, 1H, H - 5), 3.83 - 3.69 (m, 2H, CH2), 3.66 (s, 1H, H - 11), 3.60 - 3.52 (m, 2H, O - CH2), 3.50 - 3.33 (m, 4H, 3 - O - CO - NH - CH2, O - CH2, H - 5′), 3.31 - 3.21 (m, 1H, 3 - O - CO - NH - CH2), 3.08 (s, 3H, 6 - O - CH3), 3.06 - 2.69 (m, 7H, 3H - pyrrolyl, CH2, H - 3′, H - 2, H - 10), 2.68 - 2.57 (m, 2H, H - 8, H - pyrrolyl, 2.46 - 2.33 (m, 1H, H - pyrrolyl), 2.28 (s, 6H, -N(CH3)2), 2.03 - 1.78 (m, 7H, H - 4, CH2, 2H - pyrrolyl, H - 14ax, H - 7a), 1.79 - 1.70 (m, 1H, H - 4′a), 1.54 - 1.37 (m, 3H, H - 7b, H - 14eq, H - 4′b), 1.37 - 1.29 (m, 6H, 12 - CH3, 6 - CH3), 1.27 (d, J = 6.0 Hz, 3H, 5′ - CH3), 1.15 (d, J = 6.9 Hz, 3H, 2 - CH3), 1.11 (d, J = 6.8 Hz, 3H, 10 - CH3), 0.99 (d, J = 7.1 Hz, 3H, 8 - CH3), 0.79 (t, J = 7.3 Hz, 3H, 15 - CH3), 0.74 (d, J = 7.5 Hz, 3H, 4 - CH3).
[0202] Synthesis of Compound 18
[0203]
[0204] Compound 18 was prepared using compound 13 (1.50 g, 1.81 mmol) and side chain W1 (0.78 g, 2.72 mmol) as starting materials, following the general synthetic method of this preparation example. The product was recrystallized from ethyl acetate to give compound 18 (0.65 g, 0.71 mmol, 39.2%). HRMS(ESI)(M+H) + m / z 917.5503, calcd for C 48 H 77 FN4O 13 917.5482. 11H NMR (CDCl3, 400 MHz) δ: 8.09 - 8.00 (m, 2H, 2H - Bz), 7.61 - 7.54 (m, 1H, H - Bz), 7.50 - 7.41 (m, 2H, 2H - Bz), 5.47 (t, J = 5.6 Hz, 1H, CONH), 5.04 - 4.96 (m, 2H, H - 13, H - 2′), 4.83 (d, J = 11.1 Hz, 1H, H - 3), 4.30 (d, J = 7.5 Hz, 1H, H - 1′), 3.86 (d, J = 3.4 Hz, 1H, H - 5), 3.67 - 3.57 (m, 2H, O - CH2), 3.55 (s, 1H, H - 11), 3.50 - 3.34 (m, 3H, O - CH, 3 - O - CO - NH - CH2, H - 5′), 3.34 - 3.23 (m, 1H, 3 - O - CO - NH - CH2), 3.15 - 3.08 (m, 2H, - N - (CH2 - CH2)2), 3.06 (s, 3H, 6 - O - CH3), 3.02 (s, 3H, NCH3), 2.92 (q, J = 6.8 Hz, 1H, H - 10), 2.87 - 2.73 (m, 1H, H - 3′, H - 2), 2.70 - 2.59 (m, 2H, - N - (CH2 - CH2)2), 2.58 - 2.47 (m, 1H, H - 8), 2.28 (s, 6H, - N(CH3)2), 2.03 - 1.91 (m, 3H, H - 4, CH2), 1.91 - 1.80 (m, 3H, - N - (CH2 - CH2)2, H - 14ax), 1.79 - 1.71 (m, 1H, H - 4′a), 1.53 - 1.36 (m, 6H, H - 7b, H - 7a, H - 14eq, H - 4′b, - N - (CH2 - CH2)2), 1.33 - 1.28 (m, 6H, 12 - CH3, 6 - CH3), 1.26 (d, J = 6.1 Hz, 3H, 5′ - CH3), 1.11 (d, J = 6.7 Hz, 3H, 2 - CH3), 1.07 (d, J = 7.1 Hz, 3H, 8 - CH3), 1.00 (d, J = 6.7 Hz, 3H, 10 - CH3), 0.79 (t, J = 7.4 Hz, 3H, 15 - CH3), 0.75 (d, J = 7.5 Hz, 3H, 4 - CH3).
[0205] Synthesis of Compound 28
[0206]
[0207] Compound 28 was prepared using compound 13 (1.54 g, 1.87 mmol) and side chain W2 (0.69 g, 2.43 mmol) as starting materials, following the general synthetic method of this preparation example. The product was recrystallized from ethyl acetate to give compound 28 (0.98 g, 1.07 mmol, 57.2%). HRMS(ESI)(M+H) + m / z 917.5499, calcd for C 48 H 77 FN4O 13 917.5482. 1 H NMR(CDCl3,400MHz)δ:8.10-8.01(m,2H,2H-Bz),7.62-7.54(m,1H,H-Bz),7.51-7.41(m,2H,2H-Bz),5.47(t,J =5.6Hz,1H,CONH),5.04-4.96(m,2H,H-13,H-2′),4.83(d,J=11.1Hz,1H,H-3),4.30(d,J=7.5Hz,1H,H-1′),3.8 6(d,J=3.5Hz,1H,H-5),3.63-3.51(m,3H,H-11,O-CH2),3.51-3.35(m,4H,3-O-CO-NH-CH2,O-CH2,H-5′),3.31 -3.20(m,1H,3-O-CO-NH-CH2),3.08(s,3H,6-O-CH3),3.03(s,3H,NCH3),3.00-2.69(m,8H,4H-pyrrolyl,CH2,H -3′,H-2,H-10),2.58-2.48(m,1H,H-8),2.46-2.33(m,1H,H-pyrrolyl),2.28(s,6H,-N(CH3)2),2.07-1.79(m ,7H,H-4,CH2,2H-pyrrolyl,H-14ax,H-7a),1.79-1.70(m,1H,H-4′a),1.54-1.37(m,4H,H-7b,H-14eq,NH,H-4′ b),1.34-1.28(m,6H,12-CH3,6-CH3),1.26(d,J=6.0Hz,3H,5′-CH3),1.10(d,J=6.8Hz,3H,2-CH3,),1.07(d,J= 7.1Hz,3H,8-CH3),1.00(d,J=6.7Hz,3H,10-CH3),0.79(t,J=7.3Hz,3H,15-CH3),0.75(d,J=7.7Hz,3H,4-CH3).
[0208] Synthesis of Compound 19
[0209]
[0210] Using compound 14 (1.50 g, 1.78 mmol) and side chain W1 (0.76 g, 2.68 mmol) as starting materials, compound 19 was prepared according to the general synthetic method of this preparation example. The compound was purified by column chromatography (100-200 mesh silica gel, developing solvent: dichloromethane: ethanol: ammonia = 10 / 0.6 / 0.1) to give compound 19 (0.71 g, 0.76 mmol, 42.7%). HRMS (ESI) (M+H) + m / z 931.5660, calcd for C 49 H 79 FN4O 13 931.5638. 11H NMR (CDCl3, 400 MHz) δ: 8.10 - 7.99 (m, 2H, 2H - Bz), 7.61 - 7.53 (m, 1H, H - Bz), 7.50 - 7.41 (m, 2H, 2H - Bz), 5.51 (t, J = 5.5 Hz, 1H, CONH), 5.06 - 4.96 (m, 2H, H - 13, H - 2′), 4.83 (d, J = 11.1 Hz, 1H, H - 3), 4.32 (d, J = 7.5 Hz, 1H, H - 1′), 3.87 (d, J = 3.4 Hz, 1H, H - 5), 3.75 - 3.52 (m, 5H, O - CH2, H - 11, NCH2CH3), 3.50 - 3.34 (m, 3H, O - CH, 3 - O - CO - NH - CH2, H - 5′), 3.33 - 3.22 (m, 1H, 3 - O - CO - NH - CH2), 3.15 - 3.06 (m, 2H, - N - (CH2 - CH2)2), 3.04 (s, 3H, 6 - O - CH3), 2.96 (q, J = 6.7 Hz, 1H, H - 10), 2.89 - 2.73 (m, 1H, H - 3′, H - 2), 2.70 - 2.57 (m, 2H, - N - (CH2 - CH2)2), 2.57 - 2.47 (m, 1H, H - 8), 2.28 (s, 6H, - N(CH3)2), 2.06 - 1.80 (m, 5H, H - 4, CH2, - N - (CH2 - CH2)2, H - 14ax), 1.80 - 1.71 (m, 1H, H - 4′a), 1.62 - 1.35 (m, 7H, H - 7b, H - 7a, NH, H - 14eq, H - 4′b, - N - (CH2 - CH2)2), 1.33 - 1.28 (m, 6H, 12 - CH3, 6 - CH3), 1.26 (d, J = 6.4 Hz, 3H, 5′ - CH3), 1.21 (t, J = 7.1 Hz, 3H, NCH2CH3), 1.11 (d, J = 6.7 Hz, 3H, 2 - CH3), 1.08 (d, J = 7.1 Hz, 3H, 8 - CH3), 1.00 (d, J = 6.7 Hz, 3H, 10 - CH3), 0.85 - 0.70 (m, 6H, 15 - CH3, 4 - CH3).
[0211] Synthesis of Compound 29
[0212]
[0213] Using compound 14 (1.57 g, 1.87 mmol) and side chain W2 (0.69 g, 2.43 mmol) as starting materials, compound 29 was prepared according to the general synthetic method of this preparation example. The compound was purified by column chromatography (100-200 mesh silica gel, developing solvent: dichloromethane:ethanol:ammonia = 10 / 0.6 / 0.1) to give compound 29 (0.58 g, 0.62 mmol, 33.2%). HRMS (ESI) (M+H) + m / z 931.5660, calcd for C 49 H 79 FN4O 13 931.5638. 11H NMR (CDCl3, 400 MHz) δ: 8.09 - 8.00 (m, 2H, 2H - Bz), 7.62 - 7.55 (m, 1H, H - Bz), 7.50 - 7.42 (m, 2H, 2H - Bz), 5.47 (t, J = 5.6 Hz, 1H, CONH), 5.07 - 4.96 (m, 2H, H - 13, H - 2′), 4.83 (d, J = 11.4 Hz, 1H, H - 3), 4.31 (d, J = 7.5 Hz, 1H, H - 1′), 3.87 (d, J = 3.5 Hz, 1H, H - 5), 3.33 - 3.64 (m, 1H, NCH2CH3), 3.63 (s, 1H, H - 11), 3.61 - 3.51 (m, 3H, O - CH2, NCH2CH3), 3.51 - 3.36 (m, 4H, 3 - O - CO - NH - CH2, O - CH2, H - 5′), 3.30 - 3.20 (m, 1H, 3 - O - CO - NH - CH2), 3.11 - 3.05 (m, 1H, H - pyrrolyl), 3.04 (s, 3H, 6 - O - CH3), 3.02 - 2.69 (m, 6H, 3H - pyrrolyl, H - 3′, H - 2, H - 10), 2.58 - 2.46 (m, 1H, H - 8), 2.45 - 2.34 (m, 1H, H - pyrrolyl), 2.28 (s, 6H, -N(CH3)2), 2.08 - 1.79 (m, 6H, H - 4, CH2, 2H - pyrrolyl, H - 14ax), 1.79 - 1.71 (m, 1H, H - 4′a), 1.55 - 1.36 (m, 5H, H - 7b, H - 14eq, H - 7a, NH, H - 4′b), 1.33 - 1.27 (m, 6H, 12 - CH3, 6 - CH3), 1.26 (d, J = 6.1 Hz, 3H, 5′ - CH3), 1.20 (t, J = 7.2 Hz, 3H, NCH2CH3), 1.11 (d, J = 6.8 Hz, 3H, 2 - CH3,), 1.08 (d, J = 7.2 Hz, 3H, 8 - CH3), 1.00 (d, J = 6.7 Hz, 3H, 10 - CH3), 0.85 - 0.72 (m, 6H, 15 - CH3, 4 - CH3).
[0214] Synthesis of Compound 20
[0215]
[0216] Using compound 15 (1.50 g, 1.52 mmol) and side chain W1 (0.65 g, 2.27 mmol) as starting materials, compound 20 was prepared according to the general synthetic method of this preparation example. The compound was purified by column chromatography (100-200 mesh silica gel, developing solvent: dichloromethane:ethanol:ammonia = 10 / 0.6 / 0.1) to give compound 20 (0.66 g, 0.61 mmol, 40.1%). HRMS (ESI) (M+H) + m / z 1080.6102, calcd for C 57 H 86 FN5O 15 1080.6115. 11H NMR (CDCl3, 400 MHz) δ: 8.011 - 7.99 (m, 2H, 2H - Bz), 7.63 - 7.54 (m, 1H, H - Bz), 7.50 - 7.41 (m, 2H, 2H - Bz), 7.38 - 7.28 (m, 5H, Bn), 5.89 (t, J = 5.9 Hz, 1H, NH), 5.47 (t, J = 5.5 Hz, 1H, CONH), 5.18 - 4.93 (m, 4H, CH2, H - 13, H - 2′), 4.82 (d, J = 11.1 Hz, 1H, H - 3), 4.31 (d, J = 7.5 Hz, 1H, H - 1′), 4.01 - 3.88 (m, 1H, CH2), 3.86 (d, J = 3.7 Hz, 1H, H - 5), 3.75 - 3.58 (m, 4H, CH2, O - CH2), 3.56 (s, 1H, H - 11), 3.51 - 3.34 (m, 3H, 3 - O - CO - NH - CH2, O - CH, H - 5′), 3.33 - 3.15 (m, 2H, CH2, 3 - O - CO - NH - CH2), 3.16 - 3.06 (m, 2H, -N-(CH2 - CH2)2), 3.05 (s, 3H, 6 - O - CH3), 3.03 - 2.94 (m, 1H, H - 10), 2.89 - 2.73 (m, 2H, H - 8, H - 2), 2.70 - 2.58 (m, 2H, -N-(CH2 - CH2)2), 2.57 - 2.46 (m, 1H, H - 3′), 2.28 (s, 6H, -N(CH3)2), 2.02 - 1.68 (m, 7H, H - 4, CH2, -N-(CH2 - CH2)2, H - 14ax, H - 4′a), 1.54 - 1.38 (m, 6H, H - 7b, H - 7a, H - 14eq, H - 4′b, -N-(CH2 - CH2)2), 1.33 - 1.21 (m, 9H, 12 - CH3, 6 - CH3, 5′ - CH3), 1.16 - 1.04 (m, 6H, 2 - CH3, 8 - CH3), 0.89 (d, J = 6.7 Hz, 3H, 10 - CH3), 0.76 (d, J = 7.6 Hz, 3H, 4 - CH3), 0.74 (d, J = 7.2 Hz, 3H, 15 - CH3).
[0217] Synthesis of Compound 30
[0218]
[0219] Using compound 15 (1.50 g, 1.52 mmol) and side chain W2 (0.65 g, 2.27 mmol) as starting materials, compound 30 was prepared according to the general synthetic method of this preparation example. The compound was purified by column chromatography (100-200 mesh silica gel, developing solvent: dichloromethane:ethanol:ammonia = 10 / 0.6 / 0.1) to give compound 30 (0.33 g, 0.30 mmol, 19.7%). HRMS (ESI) (M+H) + m / z 1080.6117, calcd for C 57 H 86 FN5O 15 1080.6115. 1H NMR(CDCl3,400MHz)δ:8.09-7.99(m,2H,2H-Bz),7.63-7.54(m,1H,H-Bz),7.50-7.42(m,2H,2H-Bz),7.37-7.29 (m,5H,Bn),5.89(t,J=6.2Hz,1H,CONH),5.47(t,J=5.6Hz,1H,CONH),5.17-4.95(dd,4H,CH2,H-13,H-2′),4.82( d,J=11.1Hz,1H,H-3),4.31(d,J=7.5Hz,1H,H-1′),3.99-3.89(m,1H,CH2),3.87(d,J=3.7Hz,1H,H-5),3.75-3.6 4(m,2H,CH2),3.62-3.50(m,3H,H-11,O-CH2),3.49-3.35(m,4H,3-O-CO-NH-CH2,O-CH2,H-5′),3.31-3.16(m,1H ,3-O-CO-NH-CH2),3.04(s,3H,6-O-CH3),3.02-2.71(m,8H,4H-pyrrolyl,CH2,H-3′,H-2,H-10),2.59-2.47(m,1 H,H-8,2.47-2.36(m,1H,H-pyrrolyl),2.28(s,6H,-N(CH3)2),2.01-1.70(m,8H,H-4,CH2,2H-pyrrolyl,H-14ax ,H-7a,H-4′a),1.55-1.37(m,3H,H-7b,H-14eq,H-4′b),1.34-1.21(m,9H,12-CH3,6-CH3,5′-CH3),1.16-1.05(m ,6H,2-CH3,8-CH3),0.98(d,J=6.8Hz,3H,10-CH3),0.76(t,J=7.4Hz,3H,4-CH3),0.67(d,J=7.3Hz,3H,15-CH3).
[0220] Synthesis of Compound 21
[0221]
[0222] Using compound 16 (1.06 g, 1.04 mmol) and side chain W1 (0.39 g, 1.36 mmol) as starting materials, compound 21 (0.45 g, 0.41 mmol, 39.4%) was prepared according to the general synthetic method of this preparation example. The compound was purified by column chromatography (100-200 mesh silica gel, developing solvent: dichloromethane: ethanol: ammonia = 10 / 0.6 / 0.1) to give compound 21. HRMS(ESI)(M+H)+ m / z 1102.6421,calcd for C 59 H 88 N7O 13 1102.6435. 1 H NMR(CDCl3,400MHz)δ:8.94(d,J=2.2Hz,1H,H-pyridyl),8.44(dd,J=1.7Hz,4.8Hz,1H,H-pyridyl),8.14-8.00(m,3H,H-pyridyl,2H-Bz),7.65-7.54(m,2H,H-pyridyl,H-Bz),7.50-7.43(m,2H,2H-Bz),7.34(s,1H,H-imidazolyl),7.31-7.24(m,1H,H-pyridyl),5.49(t,J=5.5Hz,1H,3-O-CO-NH),5.07-4.94(m,2H,H-13,H-2′),4.82(d,J=11.1Hz,1H,H-3),4.32(d,J=7.5Hz,1H,H-1′),4.11-3.98(m,2H,CH2),3.85(d,J=3.7Hz,1H,H-5),3.80-3.63(m,2H,CONCH2),3.63-3.54(m,3H,H-11,CH2O),3.53-3.35(m,3H,H-5′,OCH,3-O-CO-NH-CH2),3.18-3.07(m,1H,3-O-CO-NH-CH2),3.16-3.06(m,2H,-N-(CH2-CH2)2),3.06-2.93(m,4H,H-10,6-O-CH3),2.89-2.75(m,2H,H-3′,H-2),2.75-2.62(m,2H,-N-(CH2-CH2)2),2.60-2.46(m,1H,H-8),2.29(s,6H,-N(CH3)2),2.06-1.62(m,11H,H-4,CH2,H-14eq,H-4′a,H-7a,H-7b,-N-(CH2-CH2)2),1.55-1.35(m,6H,2(CH2),H-14ax,H-4′b),1.33-1.20(m,9H,12-CH3,5′-CH3,6-CH3),1.13(d,J=6.7Hz,3H,10-CH3),1.09(d,J=7.1Hz,3H,8-CH3),0.98(d,J=6.7Hz,3H,2-CH3),0.82-0.69(m,6H,15-CH3,4-CH3).
[0223] Synthesis of Compound 31
[0224]
[0225] Using compound 16 (1.06 g, 1.04 mmol) and side chain W2 (0.39 g, 1.36 mmol) as starting materials, compound 31 was prepared according to the general synthetic method of this preparation example. The compound was purified by column chromatography (100-200 mesh silica gel, developing solvent: dichloromethane:ethanol:ammonia = 10 / 0.6 / 0.1) to give compound 31 (0.49 g, 0.44 mmol, 42.3%). HRMS (ESI) (M+H) + m / z 1102.6423, calcd for C 59 H 88 N7O 13 1102.6435. 1H NMR (CDCl3, 400MHz) δ: 8.94 (d, J = 2.2Hz, 1H, H-pyridyl), 8.44 (dd, J = 1.7Hz, 4.8Hz, 1H, H-pyridyl), 8.11-8.01 (m, 3H, H-pyridyl, 2H -Bz),7.63-7.52(m,2H,H-pyridyl,H-Bz),7.50-7.42(m,2H,2H-Bz),7.35(s,1H,H-imidazolyl),7.31-7.24(m,1H,H-pyridyl),5.5 4(t,J=5.6Hz,1H,3-O-CO-NH),5.07-4.93(m,2H,H-13,H-2′),4.83(d,J=11.1Hz,1H,H-3),4.32(d,J=7.6Hz,1H,H-1′),4.08-3.97(m ,2H,CH2),3.85(d,J=3.7Hz,1H,H-5),3.80-3.63(m,2H,CONCH2),3.60(s,1H,H-11),3.59-3.50(m,2H,CH2O),3.50-3.34(m,3H,H-5′, OCH,3-O-CO-NH-CH2),3.30-3.17(m,1H,3-O-CO-NH-CH2),3.14-3.05(m,1H,H-pyrrolyl),3.05-2.92(m,6H,H-10,6-O-CH3,2H-pyrr olyl),2.89-2.73(m,3H,H-3′,H-2,H-pyrrolyl),2.59-2.48(m,1H,H-8),2.49-2.36(m,3H,3H-pyrrolyl),2.28(s,6H,-N(CH3)2),2. 04-1.65(m,9H,H-4,CH2,H-14eq,H-4′a,H-7a,H-7b,CH2),1.56-1.36(m,4H,CH2,H-14ax,H-4′b),1.34-1.21(m,9H,12-CH3,5′-CH3, 6-CH3),1.13(d,J=6.7Hz,3H,10-CH3),1.09(d,J=7.1Hz,3H,8-CH3),0.98(d,J=6.7Hz,3H,2-CH3),0.82-0.68(m,6H,15-CH3,4-CH3).
[0226] Preparation Example 9: General Synthetic Method for Compounds 22-26, 32-36
[0227] Compounds 17-21, 27-31, and compound V1 (1.5-2 eq) were dissolved in acetonitrile, and triethylamine (3 eq) was added to the system. The mixture was then stirred in an oil bath at 75 °C for 8 h. After the reaction was complete, the acetonitrile was evaporated to dryness, and the product was washed with dichloromethane, water, and saturated brine to obtain an intermediate. The intermediate was dissolved in ethanol, and then an equal volume of 2M sodium hydroxide solution was added and stirred at room temperature for 1 h to remove the borate ester protecting group. The product was washed with dichloromethane, water, and saturated brine, and then the organic phase was evaporated to dryness. The residue was dissolved in methanol to remove the 2′ benzoyl protecting group to obtain the target compounds 22-26 and 32-36.
[0228] Synthesis of Compound 22
[0229]
[0230] Compound 22 (150.0 mg, 0.27 mmol) was prepared using compound 17 (0.25 g, 0.27 mmol) as the starting material, following the general synthetic method of this preparation example. After purification by column chromatography (100-200 mesh silica gel, developing solvent: dichloromethane: methanol: ammonia = 10 / 0.9 / 0.4), compound 22 was obtained. HRMS (ESI) (M+H) + m / z 1070.5825, calcd for C 54 H 81 FN7O 14 1070.5820. 1H NMR(CDCl3,400MHz)δ:8.73(s,1H,2″-quinolyl),8.06(d,J=13.3Hz,1H,5″-quinolyl),5.29(br,1H,CONH),5.09(dd,J=2.2Hz,10.9Hz,1H,H-13),4.91(d,J=11.0Hz,1H,H-3),4.21-4.09(m,2H,-N-(CH2-CH2)2),4.07-3.95(m,2H,H-1′,CH2),3.87-3.66(m,6H,-N-(CH2-CH2)2,H-5,H-11,CH2,O-CH),3.67-3.54(m,4H,1H-cyclopropyl,CH2,O-CH2),3.50-3.41(m,1H,3-O-CO-NH-CH2),3.40-3.30(m,1H,H-5′),3.29-3.14(m,2H,3-O-CO-NH-CH2,H-2′),3.08(s,3H,6-O-CH3),3.06-2.95(m,1H,CH2),2.89-2.80(m,1H,H-2),2.77(q,J=6.8Hz,1H,H-10),2.71-2.67(m,1H,H-8),2.45-2.33(m,1H,H-3′),2.27(s,6H,-N(CH3)2),2.14-2.07(m,1H,H-4),2.06-1.96(m,2H,CH2),1.95-1.69(m,6H,-N-(CH2-CH2)2,H-14ax,H-7a,),1.66-1.46(m,4H,H-4′a,H-7b,H-14eq,H-4′b),1.43(s,3H,12-CH3),1.32(s,3H,6-CH3),1.26(d,J=6.9Hz,2H,2H-cyclopropyl),1.24-1.17(m,6H,2-CH3,5′-CH3),1.14(d,J=6.8Hz,3H,10-CH3),1.11-1.05(m,5H,2H-cyclopropyl,8-CH3),1.03(d,J=7.1Hz,3H,4-CH3),0.85(t,J=7.3Hz,3H,15-CH3). 13C NMR(CDCl3,100MHz)δ:181.08,174.59,166.87,156.37,146.93,146.48,108 .89,103.27,81.91,78.64,75.63,74.07,70.51,69.54,60.15,49.46,44.43, 44.34,43.40,42.63,40.39,39.33,38.12,36.62,36.16,34.65,31.11,30.19,28.62,21.94,21.24,19.79,19.39,15.05,12.60,11.06,10.25,8.95,7.46.
[0231] Synthesis of Compound 23
[0232]
[0233] Using compound 18 (0.25 g, 0.27 mmol) as the starting material, compound 23 was prepared according to the general synthetic method of this preparation example. After purification by column chromatography (100-200 mesh silica gel, developing solvent: dichloromethane: methanol: ammonia = 10 / 0.9 / 0.4), compound 23 (184.4 mg, 0.17 mmol, 63.0%) was obtained. HRMS (ESI) (M+H) + m / z 1059.5660, calcd for C 53 H 80 FN6O 15 1059.5660. 1H NMR(CDCl3,400MHz)δ:8.72(s,1H,2″-quinolyl),8.06(d,J=13.3Hz,1H,5″-quinolyl),5.28(br,1H,CONH),5.05(dd,J=2.4Hz,11.0Hz,1H,H-13),4.87(d,J=11.0Hz,1H,H-3),4.21-4.10(m,2H,-N-(CH2-CH2)2),4.04(d,J=7.3Hz,1H,H-1′),3.81(d,J=3.1Hz,1H,H-5),3.76-3.52(m,7H,-N-(CH2-CH2)2,H-11,1H-cyclopropyl,CH-O-CH2),3.50-3.40(m,1H,3-O-CO-NH-CH2),3.40-3.31(m,1H,H-5′),3.30-3.13(m,2H,3-O-CO-NH-CH2,H-2′),3.08(s,3H,6-O-CH3),3.04(s,3H,NCH3),3.03-2.97(m,1H,H-10),2.91-2.78(m,1H,H-2),2.61-2.51(m,1H,H-8),2.45-2.33(m,1H,H-3′),2.27(s,6H,-N(CH3)2),2.18-2.06(m,1H,H-4),2.06-1.98(m,2H,CH2),1.97-1.47(m,10H,-N-(CH2-CH2)2,H-14ax,H-7a,H-4′a,H-7b,H-14eq,H-4′b),1.41(s,3H,12-CH3),1.30(s,3H,6-CH3),1.26(d,J=6.8Hz,2H,2H-cyclopropyl),1.26(d,J=6.8Hz,3H,5′-CH3),1.24-1.17(m,11H,2-CH3,10-CH3,2H-cyclopropyl,8-CH3),1.05(d,J=6.7Hz,3H,10-CH3),0.82(t,J=7.3Hz,3H,15-CH3). 13CNMR(CDCl3,100MHz)δ:215.21,157.67,146.49,82.88,80.76,78.20,74.09,70.47,69.59,66.35,62.44,49.74,45.72,44.36,43 .34,40.37,39.33,38.80,38.50,35.73,34.65,32.57,31.11,22.06,21.22,19.43,18.70,14.92,14.07,13.70,10.22,8.87,7.47.
[0234] Synthesis of Compound 24
[0235]
[0236] Compound 24 was prepared using compound 19 (0.25 g, 0.27 mmol) as the starting material, following the general synthetic method of this preparation example. After purification by column chromatography (100-200 mesh silica gel, developing solvent: dichloromethane: methanol: ammonia = 10 / 0.9 / 0.4), compound 24 (194.8 mg, 0.18 mmol, 66.7%) was obtained. HRMS (ESI) (M+H) + m / z 1073.5829, calcd for C 54 H 82 FN6O 15 1073.5817. 1H NMR(CDCl3,400MHz)δ:8.72(s,1H,2″-quinolyl),8.06(d,J=13.3Hz,1H,5″-quinolyl),5.28(t,J=5.8Hz,1H,CONH),5.07(dd,J=2.6Hz,11.0Hz,1H,H-13),4.87(d,J=11.0Hz,1H,H-3),4.21-4.08(m,2H,-N-(CH2-CH2)2),4.05(d,J=7.3Hz,1H,H-1′),3.83(d,J=3.1Hz,1H,H-5),3.78-3.51(m,8H,-N-(CH2-CH2)2,H-11,1H-cyclopropyl,CH-O-CH2,NCH2CH3),3.49-3.40(m,1H,3-O-CO-NH-CH2),3.41-3.32(m,1H,H-5′),3.29-3.13(m,3H,3-O-CO-NH-CH2,H-2′,NCH2CH3),3.11-3.07(m,1H,H-10),3.06(s,3H,6-O-CH3),2.91-2.79(m,1H,H-2),2.62-2.49(m,1H,H-8),2.45-2.34(m,1H,H-3′),2.27(s,6H,-N(CH3)2),2.18-2.07(m,1H,H-4),2.07-1.97(m,2H,CH2),1.97-1.47(m,10H,-N-(CH2-CH2)2,H-14ax,H-7a,H-4′a,H-7b,H-14eq,H-4′b),1.41(s,3H,12-CH3),1.30(s,3H,6-CH3),1.28-1.16(m,8H,2H-cyclopropyl,5′-CH3,2-CH3),1.18-1.07(m,11H,4-CH3,10-CH3,2H-cyclopropyl,NCH2CH3),1.04(d,J=7.2Hz,3H,8-CH3),0.82(t,J=7.3Hz,3H,15-CH3). 13CNMR(CDCl3,100MHz)δ:215.59,174.44,166.87,157.08,146.49,103.17,82.68,80.52,78.27,70.49,60.12,50.05,45.77,44.4 4,40.38,38.78,38.69,38.49,34.65,31.12,30.20,22.12,21.23,19.50,18.98,14.88,14.37,14.06,12.48,10.27,8.93,7.46.
[0237] Synthesis of Compound 25
[0238]
[0239] Using compound 20 (0.30 g, 0.23 mmol) as the starting material, an intermediate was obtained according to the general synthetic method of this preparation example. The intermediate was dissolved in methanol, and Pd / C (0.080 g) was added. The reaction was carried out at room temperature under a hydrogen atmosphere. After the reaction was completed, Pd / C was removed by filtration. The filtrate was evaporated to dryness and then purified by column chromatography (100-200 mesh silica gel, developing solvent: dichloromethane: methanol: ammonia = 10 / 0.9 / 0.4) to obtain compound 25 (50.2 mg, 0.046 mmol, 20.0%). HRMS (ESI) (M+H) + m / z 1088.5940, calcd for C 54 H 83 FN7O 15 1088.5926. 1H NMR(CD3OD,400MHz)δ:8.69(s,1H,2″-quinolyl),7.96(d,J=13.8Hz,1H,5″-quinolyl),5.08(dd,J=2.7Hz,10.8Hz,1H,H-13),4.81(d,J=11.0Hz,1H,H-3),4.26-4.09(m,3H,H-1′,-N-(CH2-CH2)2),3.88(d,J=3.4Hz,1H,H-5),3.82-3.54(m,9H,CH2,-N-(CH2-CH2)2,H-11,CH2-O-CH,1H-cyclopropyl),3.50-3.35(m,2H,3-O-CO-NH-CH2,H-5′),3.29-3.18(m,2H,3-O-CO-NH-CH2,H-2′),3.17-3.07(m,1H,CH2),3.04(s,3H,6-O-CH3),3.01-2.84(m,3H,CH2,H-2,H-10),2.73-2.60(m,1H,H-3′),2.58-2.47(m,1H,H-8),2.37(s,6H,-N(CH3)2),2.17-2.07(m,1H,H-4),2.07-1.92(m,2H,CH2),1.92-1.55(m,10H,-N-(CH2-CH2)2,H-14ax,H-7a,H-4′a,H-7b,H-14eq,H-4′b),1.48(s,3H,12-CH3),1.26(s,3H,6-CH3),1.23(d,J=6.4Hz,2H,2H-cyclopropyl),1.19(d,J=6.7Hz,3H,2-CH3),1.17-1.09(m,9H,5′-CH3,10-CH3,8-CH3),1.08-1.04(m,2H,2H-cyclopropyl,),1.02(d,J=6.8Hz,3H,4-CH3),0.85(t,J=7.2Hz,3H,15-CH3). 13C NMR(CD3OD,100MHz)δ:216.76,176.46,175.16,158.46,157.32,101.87,83.83, 78.39,78.09,77.65,76.98,75.94,74.03,70.80,68.79,64.92,64.40,60.82,4 9.35, 45.73, 45.31, 44.21, 43.08, 39.55, 38.71, 38.23, 37.96, 35.79, 34.08, 30.94, 29.98, 21.78, 20.07, 18.64, 17.64, 13.95, 13.34, 12.90, 9.30, 7.97, 6.48.
[0240] Synthesis of Compound 26
[0241]
[0242] Using compound 21 (0.25, 0.23 mmol) as the starting material, compound 26 was prepared according to the general synthetic method of this preparation example. After purification by column chromatography (100-200 mesh silica gel, developing solvent: dichloromethane: methanol: ammonia = 10 / 0.9 / 0.4), compound 26 (111.3 mg, 0.089 mmol, 38.7%) was obtained. HRMS (ESI) (M+H) + m / z 1244.6611, calcd for C 64 H 91 FN9O 15 1244.6613. 1H NMR(CDCl3,400MHz)δ:8.94(d,J=2.2Hz,1H,H-pyridyl),8.72(s,1H,2″-quinolyl),8.44(dd,J=1.7Hz,4.8Hz,1H,H-pyridyl),8.12-7.99(m,2H,5″-quinolyl,H-pyridyl),7.55(s,1H,H-imidazolyl),7.37(s,1H,H-imidazolyl),7.32-7.24(m,1H,H-pyridyl),5.34(br,1H,CONH),5.04(dd,J=2.4Hz,10.9Hz,1H,H-13),4.86(d,J=11.0Hz,1H,H-3),4.23-4.09(m,2H,-N-(CH2-CH2)2),4.10-3.97(m,3H,H-1′,CH2),3.87-3.73(m,2H,H-5,CONCH2),3.73-3.50(m,8H,H-11,H-cyclopropyl,CHOCH2,CONCH2,-N-(CH2-CH2)2),3.48-3.30(m,3H,H-5′,OCH2,3-O-CO-NH-CH2),3.28-3.14(m,2H,H-2′,3-O-CO-NH-CH2),3.10(q,J=6.9Hz,1H,H-10),3.04(s,3H,6-O-CH3),2.93-2.81(m,1H,H-2),2.63-2.50(m,1H,H-8),2.46-2.32(m,1H,H-3′),2.27(s,6H,-N(CH3)2),2.18-2.07(m,1H,H-4),2.07-1.80(m,8H,-N-(CH2-CH2)2,CH2,H-4′a,H-14ax),1.80-1.50(m,8H,H-7a,H-4′b,H-14eq,2(CH2),H-7b),1.42(m,3H,12-CH3),1.28(s,3H,6-CH3),1.27-1.19(m,5H,5′-CH3,2H-cyclopropyl),1.19-1.06(m,11H,2-CH3,8-CH3,10-CH3,2H-cyclopropyl),1.03(d,J=6.7Hz,4-CH3),0.77(t,J=7.3Hz,3H,15-CH3). 13C NMR(CDCl3,100MHz)δ:215.81,177.09,166.87,157.43,147.57,146.91,146.47,139.05, 137.80,131.98,130.34,123.51,115.60,108.88,87.74,82.80,78.39,70.46,69.62,66. 11,56.32,56.22,50.17,46.93,45.81,44.46,43.15,42.70,40.36,38.84,38.53,34.64,31.13,28.84,24.34,22.11,21.22,19.50,19.00,14.89,14.36,14.19,10.36,8.88,7.46.
[0243] Synthesis of Compound 32
[0244]
[0245] Compound 27 (0.25 g, 0.27 mmol) was used as the starting material and prepared according to the general synthetic method of this preparation example. After purification by column chromatography (100-200 mesh silica gel, developing solvent: dichloromethane: methanol: ammonia = 10 / 0.9 / 0.4), compound 32 (182.8 mg, 0.17 mmol, 63.0%) was obtained. HRMS (ESI) (M+H) + m / z 1070.5862, calcd for C 54 H 81 FN7O 14 1070.5820. 1H NMR(CDCl3,400MHz)δ:8.66(s,1H,2″-quinolyl),7.95(d,J=12.5Hz,1H,5″-quinolyl),5.26(d,J=5.8Hz,1H,CONH),5.09(dd,J=2.2Hz,11.0Hz,1H,H-13),4.91(d,J=11.0Hz,1H,H-3),4.07-3.92(m,3H,1H-pyrrolyl,H-1′,CH2),3.88-3.74(m,4H,1H-pyrrolyl,H-5,CH2),3.72(s,1H,H-11),3.66-3.60(m,1H,1H-cyclopropyl),3.57(t,J=11.0Hz,OCH2),3.52(d,J=6.5Hz,OCH2),3.47-3.31(m,2H,3-O-CO-NH-CH2,H-5′),3.30-3.14(m,3H,1H-pyrrolyl,3-O-CO-NH-CH2,H-2′),3.08(s,3H,6-O-CH3),3.05-2.94(m,1H,CH2),2.87-2.72(m,2H,H-2,1H-pyrrolyl),2.72-2.59(m,2H,H-10,H-8),2.46-2.35(m,1H,H-3′),2.28(s,6H,-N(CH3)2),2.23-2.13(m,1H,1H-pyrrolyl),2.14-2.05(m,1H,H-4),1.96-1.74(m,5H,2H-pyrrolyl,H-14ax,H-7a,CH2),1.69-1.44(m,4H,H-4′a,H-7b,H-14eq,H-4′b),1.42(s,3H,12-CH3),1.32(s,3H,6-CH3),1.29-1.17(m,8H,2H-cyclopropyl,2-CH3,5′-CH3),1.13(d,J=6.8Hz,3H,10-CH3),1.10-0.98(m,8H,2H-cyclopropyl,8-CH3,4-CH3),0.82(t,J=7.3Hz,3H,15-CH3). 13C NMR(CDCl3,100MHz)δ:181.08,176.90,174.57,167.04,156.37,149.06,147.52,145.9 0,118.05,117.85,108.65,103.26,81.91,80.89,78.64,78.15,75.62,72.21,70.51,6 9.53, 66.11, 60.15, 49.46, 43.40, 42.63, 40.37, 39.20, 38.13, 36.62, 36.13, 34.65, 29.88, 28.62, 21.93, 21.24, 19.79, 19.39, 15.04, 12.57, 11.06, 10.25, 8.94, 7.46, 7.35.
[0246] Synthesis of Compound 33
[0247]
[0248] Using compound 28 (0.25 g, 0.27 mmol) as the starting material, compound 33 was prepared according to the general synthetic method of this preparation example. After purification by column chromatography (100-200 mesh silica gel, developing solvent: dichloromethane: methanol: ammonia = 10 / 0.9 / 0.4), compound 33 (221.3 mg, 0.21 mmol, 77.8%) was obtained. HRMS (ESI) (M+H) + m / z 1059.5678, calcd for C 53 H 80 FN6O 15 1059.5660. 1H NMR(CDCl3,400MHz)δ:8.65(s,1H,2″-quinolyl),7.95(d,J=12.4Hz,1H,5″-quinolyl),5.26(d,J=5.8Hz,1H,CONH),5.09(dd,J=2.2Hz,11.0Hz,1H,H-13),4.91(d,J=11.0Hz,1H,H-3),4.01-3.91(m,2H,1H-pyrrolyl,H-1′),3.87-3.73(m,2H,1H-pyrrolyl,H-5),3.67-3.47(m,6H,H-11,1H-cyclopropyl,CH2OCH2),3.47-3.33(m,2H,3-O-CO-NH-CH2,H-5′),3.31-3.15(m,3H,1H-pyrrolyl,3-O-CO-NH-CH2,H-2′),3.08(s,3H,6-O-CH3),3.03(s,3H,NCH3),3.02-2.94(m,1H,H-10),2.88-2.75(m,1H,H-2),2.73-2.61(m,1H,1H-pyrrolyl),2.61-2.50(m,1H,H-8),2.47-2.34(m,1H,H-3′),2.28(s,6H,-N(CH3)2),2.23-2.15(m,1H,1H-pyrrolyl),2.15-2.06(m,1H,H-4),1.99-1.76(m,6H,2H-pyrrolyl,H-14ax,H-7a,CH2),1.77-1.47(m,4H,H-4′a,H-7b,H-14eq,H-4′b),1.41(s,3H,12-CH3),1.30(s,3H,6-CH3),1.28-1.17(m,5H,2H-cyclopropyl,5′-CH3),1.18-0.97(m,14H,10-CH3,2-CH3,2H-cyclopropyl,8-CH3,4-CH3),0.82(t,J=7.3Hz,3H,15-CH3). 13C NMR(CDCl3,100MHz)δ:215.22,174.59,167.05,157.67,156.36,147.51,145 .91,103.18,82.89,80.71,78.20,76.15,72.24,70.48,69.59,66.11,62.44, 49.74,45.72,43.33,40.36,38.79,38.50,35.71,34.64,32.57,29.87,28.53,22.04,21.21,19.43,18.70,14.91,14.07,13.67,10.23,8.87,7.45,7.34.
[0249] Synthesis of Compound 34
[0250]
[0251] Compound 29 (0.25 g, 0.27 mmol) was used as the starting material and prepared according to the general synthetic method of this preparation example. After purification by column chromatography (100-200 mesh silica gel, developing solvent: dichloromethane: methanol: ammonia = 10 / 0.9 / 0.4), compound 34 (146.2 mg, 0.14 mmol, 51.8%) was obtained. HRMS (ESI) (M+H) + m / z 1073.5835, calcd for C 54 H 82 FN6O 15 1073.5817. 1H NMR(CDCl3,400MHz)δ:8.66(s,1H,2″-quinolyl),7.96(d,J=12.4Hz,1H,5″-quinolyl),5.25(d,J=6.0Hz,1H,CONH),5.07(dd,J=2.2Hz,11.0Hz,1H,H-13),4.86(d,J=11.0Hz,1H,H-3),4.09-3.91(m,2H,1H-pyrrolyl,H-1′),3.88-3.76(m,2H,1H-pyrrolyl,H-5),3.75-3.47(m,7H,H-11,1H-cyclopropyl,CH2OCH2,NCH2CH3),3.47-3.32(m,3H,3-O-CO-NH-CH2,H-5′,NCH2CH3),3.33-3.13(m,3H,1H-pyrrolyl,3-O-CO-NH-CH2,H-2′),3.05(s,3H,6-O-CH3),3.04-2.69(m,1H,H-10),2.91-2.78(m,1H,H-2),2.73-2.61(m,1H,1H-pyrrolyl),2.61-2.49(m,1H,H-8),2.48-2.35(m,1H,H-3′),2.28(s,6H,-N(CH3)2),2.23-2.05(m,2H,1H-pyrrolyl,H-4),2.01-1.45(m,10H,2H-pyrrolyl,H-14ax,H-7a,CH2,H-4′a,H-7b,H-14eq,H-4′b),1.40(s,3H,12-CH3),1.30(s,3H,6-CH3),1.28-1.18(m,8H,2H-cyclopropyl,5′-CH3,10-CH3),1.18-1.08(m,14H,2-CH3,2H-cyclopropyl,4-CH3),1.04(d,J=7.3Hz,3H,8-CH3),0.82(t,J=7.3Hz,3H,15-CH3). 13C NMR(CDCl3,100MHz)δ:13CNMR(101MHz,CDCl3)δ215.59,174.43,167.05,157.09,145.94,117.92,82.68,80.50,78.27,76.30,70.48,69.59,60.12, 50.04,45.78,43.23,40.36,38.70,38.49,35.68,34.63,29.88,28.53,22 .11,21.22,19.49,18.99,14.87,14.37,14.02,12.48,10.27,8.92,7.35.
[0252] Synthesis of Compound 35
[0253]
[0254] Using compound 30 (0.33 g, 0.23 mmol) as the starting material, an intermediate was obtained according to the general synthetic method of this preparation example. The intermediate was dissolved in methanol, and Pd / C (0.080 g) was added. The reaction was carried out at room temperature under a hydrogen atmosphere. After the reaction was completed, Pd / C was removed by filtration. The filtrate was evaporated to dryness and then purified by column chromatography (100-200 mesh silica gel, developing solvent: dichloromethane:methanol:ammonia = 10 / 0.9 / 0.4) to obtain compound 35 (51.0 mg, 0.047 mmol, 20.4%). HRMS (ESI) (M+H) + m / z 1088.5905, calcd for C 54 H 83 FN7O 15 1088.5926. 1H NMR(CD3OD,400MHz)δ:8.61(s,1H,2″-quinolyl),7.83(d,J=13.3Hz,1H,5″-quinolyl),5.02(dd,J=2.4Hz,10.9Hz,1H,H-13),4.75(d,J=11.1Hz,1H,H-3),4.12(d,J=7.3Hz,1H,H-1′),4.02-3.86(m,2H,2H-pyrrolyl),3.86-3.76(m,2H,H-5,CH2),3.76-3.60(m,5H,H-11,H-pyrrolyl,1H-cyclopropyl,OCH2),3.58-3.48(m,4H,OCH2,H-pyrrolyl,CH2),3.48-3.36(m,3H,3-O-CO-NH-CH2,H-pyrrolyl,H-5′),3.28-3.14(m,2H,3-O-CO-NH-CH2,H-2′),3.13-3.00(m,3H,H-10,CH2),2.97(s,3H,6-O-CH3),2.90-2.80(m,1H,H-2),2.70-2.58(m,2H,H-3′,1H-pyrrolyl),2.57-2.46(m,1H,H-8),2.35(s,6H,-N(CH3)2),2.22-2.09(m,1H,1H-pyrrolyl),2.09-1.99(m,1H,H-4),1.91-1.69(m,6H,H-14ax,H-7a,CH2,H-4′a,H-4′b),1.69-1.44(m,2H,H-7b,H-14eq),1.45(s,3H,12-CH3),1.30-1.20(m,5H,6-CH3,2H-cyclopropyl),1.18(d,J=6.0Hz,3H,5′-CH3),1.14(d,J=7.1Hz,3H,2-CH3),1.10(d,J=7.5Hz,3H,4-CH3),1.07-0.69(m,8H,2H-cyclopropyl,8-CH3,10-CH3),0.81(t,J=7.3Hz,3H,15-CH3). 13C NMR(CD3OD,100MHz)δ:216.64,174.95,158.47,157.10,147.14,101.85,83.8 4,78.34,77.75,76.89,75.82,72.08,70.83,68.81,64.38,60.95,49.30,45. 69,45.26,43.09,39.58,38.65,38.24,38.11,37.68,35.66,34.00,30.93,29.47,21.75,20.07,18.63,17.63,13.88,13.35,12.85,9.30,7.98,6.54,6.34.
[0255] Synthesis of Compound 36
[0256]
[0257] Compound 31 (0.25, 0.23 mmol) was used as the starting material and prepared according to the general synthetic method of this preparation example. The compound was purified by column chromatography (100-200 mesh silica gel, developing solvent: dichloromethane: methanol: ammonia = 10 / 0.9 / 0.4) to give compound 36 (113.0 mg, 0.091 mmol, 39.5%). HRMS (ESI) (M+H) + m / z 1244.6597, calcd for C 64 H 91 FN9O 15 1244.6613. 1H NMR(CDCl3,400MHz)δ:8.94(d,J=2.2Hz,1H,H-pyridyl),8.63(s,1H,2″-quinolyl),8.43(dd,J=1.7Hz,4.8Hz,1H,H-pyridyl),8.07(dt,J=2.0Hz,7.9Hz,1H,H-pyridyl),7.93(d,J=12.5Hz,1H,5″-quinolyl),7.55(s,1H,H-imidazolyl),7.36(s,1H,H-imidazolyl),7.32-7.22(m,1H,H-pyridyl),5.33(br,1H,CONH),5.03(dd,J=2.4Hz,11.0Hz,1H,H-13),4.86(d,J=10.9Hz,1H,H-3),4.15-3.88(m,5H,2H-pyrrolyl,CH2,H-1′),3.88-3.73(m,3H,H-5,H-pyrrolyl,CONCH2),3.73-3.48(m,9H,H-11,H-cyclopropyl,CH2OCH2,CONCH2,2H-pyrrolyl),3.48-3.13(m,2H,H-5′,3-O-CO-NH-CH2),3.29-3.13(m,2H,H-2′,3-O-CO-NH-CH2),3.10(q,J=6.9Hz,1H,H-10),3.04(s,3H,6-O-CH3),2.92-2.79(m,1H,H-2),2.72-2.50(m,2H,H-8,H-pyrrolyl),2.47-2.34(m,1H,H-3′),2.28(s,6H,-N(CH3)2),2.24-2.05(m,2H,H-4,H-pyrrolyl),1.99-1.77(m,6H,2(CH2),H-4′a,H-14ax),1.76-1.49(m,6H,H-7a,H-4′b,H-14eq,CH2,H-7b),1.41(m,3H,12-CH3),1.29(s,3H,6-CH3),1.27-1.18(m,5H,5′-CH3,2H-cyclopropyl),1.19-1.05(m,11H,2-CH3,8-CH3,10-CH3,2H-cyclopropyl),1.03(d,J=6.8Hz,4-CH3),0.77(t,J=7.2Hz,3H,15-CH3). 13CNMR(CDCl3,100MHz)δ:215.86,176.95,174.83,167.10,157.48,147.60,146.46,145.92,139 .08,137.85,132.01,130.39,123.55,115.67,87.78,82.86,78.45,70.52,60.20,56.40,56.36 ,56.35,56.33,56.31,56.29,50.22,46.98,45.86,43.22,42.76,40.42,38.89,38.57,34.70,29.91,28.89,24.40,22.15,21.27,19.55,19.05,14.94,14.41,14.22,10.41,8.93,7.51,7.39.
[0258] The following examples illustrate the preparation process of compounds 37-47 of the present invention, with the following reaction formulas:
[0259]
[0260] Reaction conditions and reagents: a.1) Pd / C, methanol, room temperature; 2) Boc anhydride, triethylamine, dichloromethane; 3) CDI, DMAP, dichloromethane, room temperature.
[0261]
[0262] Reaction conditions and reagents: a. Octynylamine hydrochloride, DMF, room temperature; b. Compound V2, CuI, Pd(PPh3)2Cl2, triethylamine, acetonitrile, 70℃; c. 1) Lithium hydroxide monohydrate, water / THF (1:1), room temperature; 2) Methanol reflux. d. 1,3-Propanediamine, DMF, room temperature; e. Formic acid, NaNO2, 3-Butyn-1-ol, -15℃; f. Compound V2, CuI, Pd(PPh3)2Cl2, triethylamine, acetonitrile, 70℃; g. 1) Lithium hydroxide monohydrate, water / THF (1:1), room temperature; 2) Methanol reflux.
[0263] Preparation Example 10: Synthesis of Compound 37
[0264] Compound 10 (3.90 g, 3.37 mmol) was dissolved in methanol, and Pd / C (0.15 g) was added. The mixture was stirred at room temperature for 8 h under a hydrogen atmosphere. After the reaction was complete, the mixture was filtered, and the filtrate was evaporated to dryness. The dried product (2.67 g, 3.12 mmol) was dissolved in dichloromethane, and Boc anhydride (1.02 g, 4.68 mmol) and triethylamine (1.30 mL, 9.365 mmol) were added under ice bath conditions. The mixture was reacted at room temperature for 1 h. After the reaction was complete, the dichloromethane layer was washed with water, saturated sodium bicarbonate, and saturated brine, respectively. The organic phase was evaporated to dryness to obtain the crude product. The crude product was purified by column chromatography (100-200 mesh silica gel, developing solvent: dichloromethane: ethanol: ammonia = 10 / 0.2 / 0.1) to obtain the intermediate (2.54 g, 2.95 mmol, 87.5%).
[0265] The intermediate obtained above (2.54 g, 2.95 mmol) was reacted with CDI, DMAP, dichloromethane, and at room temperature to give compound 37 (2.11 g, 2.21 mmol, 74.9%).
[0266] Preparation Example 11: General Synthetic Method for Compounds 38-41
[0267] Compounds 12-14 and 37 (1 eq) were dissolved in DMF, and octyryne amine hydrochloride (1.5 eq) and DBU (3 eq) were added dropwise at room temperature. The reaction was carried out at room temperature for 12 h. The reaction progress was monitored by TLC. After the reaction was complete, ethyl acetate was added, and the organic layer was washed three times with water and once with saturated brine. The organic phase was evaporated to dryness to give compounds 38-41.
[0268] Synthesis of Compound 38
[0269]
[0270] Compound 38 was prepared using compound 12 (0.61 g, 0.73 mmol) as a starting material via the general synthetic method of this preparation example. The product was recrystallized from ethyl acetate to give compound 38 (0.26 g, 0.29 mmol, 39.7%).
[0271] Synthesis of Compound 39
[0272]
[0273] Using compound 13 (0.80 g, 0.97 mmol) as a starting material, compound 39 was prepared by the general synthetic method of this preparation example. The product was recrystallized from ethyl acetate to give compound 39 (0.25 g, 0.28 mmol, 28.9%).
[0274] Synthesis of Compound 40
[0275]
[0276] Using compound 14 (0.85 g, 1.01 mmol) as a starting material, compound 40 was prepared by the general synthetic method of this preparation example. The product was recrystallized from ethyl acetate to give compound 40 (0.26 g, 0.29 mmol, 28.7%).
[0277] Synthesis of Compound 41
[0278]
[0279] Using compound 37 (0.90 g, 0.94 mmol) as the starting material, compound 41 (0.30 g, 0.29 mmol, 30.8%) was prepared by the general synthetic method of this preparation example. The product was purified by column chromatography (100-200 mesh silica gel, developing solvent: dichloromethane: ethanol: ammonia = 10 / 0.1 / 0.1) to give compound 41 (0.30 g, 0.29 mmol, 30.8%).
[0280] Preparation Example 12: General Synthetic Method for Compounds 42-45, 47
[0281] Compound 3 (1 eq), bis(triphenylphosphine)palladium dichloride (0.05 eq), compound V2 (1.2 eq), cuprous iodide (0.1 eq), and triethylamine (1.5 eq) were added to a pressure-resistant flask. After venting, the flask was sealed and transferred to a 75°C bath for reaction over 4 h. After the reaction was monitored, 30 mL of dichloromethane was added to the reaction system, followed by washing with water, saturated sodium bicarbonate, and saturated sodium chloride solutions, and the organic phase was evaporated to dryness. The product was dissolved in methanol and refluxed overnight. After the reaction was complete, the reaction solution was evaporated to dryness to obtain the intermediate. The product was then dissolved in water / THF (1:1), and lithium hydroxide monohydrate (2 eq) was added. The reaction was carried out at room temperature for 2 h, and the mixture was purified by column chromatography to obtain compounds 42-45 and 47.
[0282] Synthesis of Compound 42
[0283]
[0284] Compound 38 (0.20 g, 0.22 mmol) was used as the starting material and prepared using the general synthetic method of this preparation example. The compound was purified by column chromatography (100-200 mesh silica gel, developing solvent: dichloromethane: methanol: ammonia = 10 / 0.9 / 0.4) to give compound 42 (94.9 mg, 0.096 mmol, 43.6%). HRMS (ESI) (M+H) + m / z 992.55539, calcd for C 53 H 78 N5O 13 992.55906. 1H NMR(CD3OD,400MHz)δ:8.81(s,1H,2″-quinolyl),8.30(d,J=8.3Hz,1H,5″-quinolyl),7.70(br,1H,8″-quinolyl),7.40(br,1H,6″-quinolyl),5.02(dd,J=2.2Hz,10.7Hz,1H,H-13),4.85(d,J=11.0Hz,1H,H-3),4.13(d,J=7.3Hz,1H,H-1′),4.07-3.91(m,4H,CH2,NCH3),3.90-3.77(m,2H,H-5,CH2),3.76-3.62(m,2H,H-11,CH2),3.53-3.39(m,1H,H-5′),3.29-3.21(m,2H,3-O-CO-NH-CH2,H-2′),3.07(s,3H,6-O-CH3),3.05-2.97(m,2H,3-O-CO-NH-CH2,CH2),2.99-2.90(m,1H,H-10),2.90-2.82(m,1H,H-2),2.82-2.73(m,1H,H-3′),2.73-2.63(m,1H,H-8),2.56-2.46(m,2H,CH2-C≡C-),2.43(s,6H,-N(CH3)2),2.13-1.98(m,1H,H-4),1.89-1.72(m,2H,CH2),1.73-1.36(m,14H,3(CH2),H-14ax,H-7a,H-4′a,H-7b,H-14eq,12-CH3),1.32(s,3H,6-CH3),1.28-1.23(m,1H,H-4′b),1.24-1.16(m,6H,2-CH3,5′-CH3),1.15-1.02(m,9H,10-CH3,8-CH3,4-CH3),0.82(t,J=7.5Hz,3H,15-CH3). 13C NMR(CD3OD,100MHz)δ:174.95,157.39,156.81,101.73,82.49,79.50,78.6 2,78.11,77.20,75.17,70.60,68.65,64.55,60.19,48.66,43.21,42.35,42 .16,40.95,40.44,39.50,37.83,36.71,36.00,30.91,29.39,28.27,28.13,25.99,21.64,20.03,18.69,18.52,18.41,14.00,11.46,9.88,9.42,8.02.
[0285] Synthesis of Compound 43
[0286]
[0287] Compound 39 (0.20 g, 0.23 mmol) was used as the starting material and prepared using the general synthetic method of this preparation example. The compound was purified by column chromatography (100-200 mesh silica gel, developing solvent: dichloromethane: methanol: ammonia = 10 / 0.9 / 0.4) to give compound 43 (123.9 mg, 0.13 mmol, 56.5%). HRMS (ESI) (M+H) + m / z 981.54130, calcd for C 52 H 77 N4O 14 981.54308. 1H NMR(CD3OD,400MHz)δ:8.80(s,1H,2″-quinolyl),8.30(d,J=8.3Hz,1H,5″-quinolyl),7.73(br,1H,8″-quinolyl),7.43(br,1H,6″-quinolyl),4.98(dd,J=2.2Hz,10.7Hz,1H,H-13),4.83(d,J=11.0Hz,1H,H-3),4.14(d,J=7.3Hz,1H,H-1′),3.99(s,3H,NCH3),3.87(d,J=3.1Hz,1H,H-5),3.65(s,1H,H-11),3.51-3.38(m,1H,H-5′),3.29-3.21(m,2H,3-O-CO-NH-CH2,H-2′),3.21-3.11(m,1H,H-10),3.10-2.95(m,7H,NCH3,6-O-CH3,3-O-CO-NH-CH2),2.94-2.81(m,1H,H-2),2.82-2.64(m,1H,H-3′),2.57-2.46(m,3H,H-8,CH2-C≡C-),2.42(s,6H,-N(CH3)2),2.18-2.03(m,1H,H-4),1.90-1.71(m,3H,CH2,H-14ax),1.71-1.35(m,13H,3(CH2),H-7a,H-4′a,H-7b,H-14eq,12-CH3),1.36-1.29(m,1H,H-4′b),1.26(s,3H,6-CH3),1.21-1.06(m,12H,2-CH3,5′-CH3,10-CH3,4-CH3),1.02(d,J=6.5Hz,3H,8-CH3),0.82(t,J=7.4Hz,3H,15-CH3). 13 C NMR(CD3OD,100MHz)δ:216.49,174.95,158.46,157.39,101.69,83.69,79.46,78.22,78.05,77.18,75.66,70.64,68.68,64.50,62.57,48.90,45.69,43.18,40.99,40.48,39.50,38.63,38.13,35.64,31.72,30.88,29.40,28.30,28.12,26.02,21.74,20.02,18.69,18.57,17.45,13.87,13.06,12.49,9.38,7.97.
[0288] Synthesis of Compound 44
[0289]
[0290] Compound 40 (0.20 g, 0.22 mmol) was used as the starting material and prepared using the general synthetic method of this preparation example. The compound was purified by column chromatography (100-200 mesh silica gel, developing solvent: dichloromethane: methanol: ammonia = 10 / 0.9 / 0.4) to give compound 44 (103.8 mg, 0.10 mmol, 45.5%). HRMS (ESI) (M+H) + m / z 995.55606, calcd for C 53 H 79 N4O 14 995.55873. 1H NMR(CD3OD,400MHz)δ:8.81(s,1H,2″-quinolyl),8.30(d,J=8.3Hz,1H,5″-quinolyl),7.69(br,1H,8″-quinolyl),7.39(br,1H,6″-quinolyl),5.04(dd,J=2.2Hz,10.6Hz,1H,H-13),4.83(d,J=11.0Hz,1H,H-3),4.16(d,J=7.2Hz,1H,H-1′),3.98(s,3H,NCH3),3.87(d,J=3.1Hz,1H,H-5),3.73(s,1H,H-11),3.66-3.50(m,2H,NCH2CH3),3.50-3.37(m,1H,H-5′),3.28-3.21(m,2H,3-O-CO-NH-CH2,H-2′),3.20-3.14(m,1H,H-10),3.11-2.97(m,4H,6-O-CH3,3-O-CO-NH-CH2),2.95-2.84(m,1H,H-2),2.82-2.73(m,1H,H-3′),2.58-2.46(m,3H,H-8,CH2-C≡C-),2.44(s,6H,-N(CH3)2),2.19-2.07(m,1H,H-4),1.90-1.71(m,3H,CH2,H-14ax),1.72-1.34(m,13H,3(CH2),H-7a,H-4′a,H-7b,H-14eq,12-CH3),1.26(s,3H,6-CH3),1.23-1.06(m,13H,H-4′b,2-CH3,5′-CH3,10-CH3,4-CH3),1.01(d,J=6.5Hz,3H,8-CH3),0.82(t,J=7.5Hz,3H,15-CH3). 13 C NMR(CD3OD,100MHz)δ:216.80,174.84,157.86,157.40,101.63,83.49,79.48,78.30,77.85,77.09,75.79,70.62,68.65,64.50,60.38,49.16,45.73,43.08,40.94,40.50,39.51,38.61,38.53,38.13,35.61,29.41,28.32,28.14,26.04,21.79,20.03,18.70,18.63,17.70,13.87,13.37,12.85,11.48,9.41,8.02.
[0291] Synthesis of Compound 45
[0292]
[0293] Using compound 41 (0.25 g, 0.25 mmol) as the starting material, the intermediate was prepared using the general synthetic method of this preparation example. After the reaction was complete, the intermediate was dissolved in ethanol (4 mL), and 2 mL of 12 M HCl was added dropwise. The reaction was carried out at room temperature to remove the Boc protecting group. After the reaction was complete, dichloromethane was added, and the pH was adjusted to 10 with ammonia. The mixture was then washed with water and saturated brine, and purified by organic phase column chromatography (100-200 mesh silica gel, developing solvent: dichloromethane: methanol: ammonia = 10 / 0.9 / 0.4) to give compound 45 (56.4 mg, 0.056 mmol, 22.4%). HRMS (ESI) (M+H) + m / z1010.56576, calcd for C 53 H 80 N5O 14 1010.56963. 1H NMR(CD3OD,400MHz)δ:8.73(s,1H,2″-quinolyl),8.28(d,J=8.3Hz,1H,5″-quinolyl),7.68(br,1H,8″-quinolyl),7.44(d,J=8.3Hz,1H,6″-quinolyl),5.04(dd,J=2.2Hz,10.7Hz,1H,H-13),4.79(d,J=11.2Hz,1H,H-3),4.12(d,J=7.3Hz,1H,H-1′),3.97(s,3H,NCH3),3.85(d,J=3.2Hz,1H,H-5),3.82-3.59(m,3H,H-11,CH2),3.50-3.37(m,1H,H-5′),3.37-3.32(m,1H,3-O-CO-NH-CH2),3.26-3.15(m,2H,3-O-CO-NH-CH2,H-2′),3.16-3.01(m,1H,H-2,CH2),2.99(s,3H,6-O-CH3),2.93-2.84(m,1H,H-8),2.72-2.59(m,1H,H-3′),2.60-2.44(m,3H,H-10,CH2-C≡C-),2.36(s,6H,-N(CH3)2),2.16-1.99(m,1H,H-4),1.89-1.70(m,3H,CH2,H-14ax),1.70-1.36(m,13H,3(CH2),H-7a,H-4′a,H-7b,H-14eq,12-CH3),1.35-1.26(m,1H,H-4′b),1.23(s,3H,6-CH3),1.21-1.05(m,12H,2-CH3,5′-CH3,10-CH3,4-CH3),1.02(d,J=6.6Hz,3H,8-CH3),0.82(t,J=7.3Hz,3H,15-CH3).. 13C NMR(CD3OD,100MHz)δ:216.73,177.03,175.11,158.44,157.35,126.45,119.25 ,101.86,94.32,83.92,79.76,78.35,77.62,76.83,75.78,70.79,68.78,64.38, 60.89,49.35,45.71,43.08,40.75,40.18,39.53,38.68,38.09,35.76,30.85,29.21,28.00,25.69,21.74,20.08,18.63,17.60,13.89,13.33,12.84,9.25,7.94.
[0294] Synthesis of Compound 46
[0295]
[0296] Compound 12 (2.50 g, 2.98 mmol) was dissolved in DMF, and propylenediamine (0.77 mL, 8.95 mmol) was added dropwise. The reaction was carried out at room temperature for 2 h. After the reaction was complete, ethyl acetate was added, and the organic phase was washed with saturated sodium bicarbonate solution, water, and saturated brine, respectively. The organic layer was evaporated to dryness and purified by column chromatography (100-200 mesh silica gel, developing solvent: dichloromethane: ethanol: ammonia = 10 / 0.8 / 0.1) to give the intermediate (1.60 g, 2.16 mmol, 72.5%).
[0297] 3-Butyn-1-ol (4.55 mL, 64.87 mmol) was added as a solvent to the intermediate (1.60 g, 2.16 mmol) obtained in the previous steps. The system was transferred to -20 °C, and formic acid (0.37 mL, 9.73 mmol) was added dropwise. Then, sodium nitrite (0.90 g, 12.97 mmol) was added in portions while stirring. The temperature was maintained overnight, and then the reaction was slowly raised to room temperature for 12 h. After the reaction was completed by TLC monitoring, 20 mL of dichloromethane and 20 mL of distilled water were added to the system. The organic phase was washed with saturated sodium bicarbonate solution, water, and saturated brine, respectively. The organic layer was evaporated to dryness, and the product was recrystallized from ethyl acetate to give compound 46 (0.83 g, 0.92 mmol, 42.6%).
[0298] Synthesis of Compound 47
[0299]
[0300] Compound 46 (0.20 g, 0.23 mmol) was used as the starting material and prepared using the general synthetic method of this preparation example. The compound was purified by column chromatography (100-200 mesh silica gel, developing solvent: dichloromethane: methanol: ammonia = 10 / 0.9 / 0.4) to give compound 47 (45.3 mg, 0.046 mmol, 20.0%). HRMS (ESI) (M+H) + m / z 994.53505, calcd for C 52 H 76 N5O 14 994.53833. 1 H NMR (CD3OD, 400MHz) δ: 8.83 (s, 1H, 2″-quinolyl), 8.31 (d, J = 8.0Hz, 1H, 5″-quinolyl), 7.77 (br, 1H, 8″ -quinolyl),7.47(br,1H,6″-quinolyl),5.01(dd,J=2.2Hz,10.7Hz,1H,H-13),4.83(d,J=11.0Hz,1H, H-3),4.12(d,J=7.3Hz,1H,H-1′),4.07-3.91(m,4H,CH2,NCH3),3.90-3.76(m,2H,H-5,CH2),3.77-3.5 2(m,6H,H-11,CH2,CH2OCH2),3.49-3.34(m,2H,H-5′,3-O-CO-NH-CH2),3.28-3.15(m,2H,3-O-CO-NH-C H2,H-2′),3.07(s,3H,6-O-CH3),3.03-2.87(m,2H,CH2,H-2),2.86-2.58(m,5H,H-3′,H-10,H-8,CH2-C ≡C-),2.44(s,6H,-N(CH3)2),2.12-1.98(m,1H,H-4),1.90-1.73(m,4H,CH2,H-14ax,H-7a),1.72-1.49 (m,3H,H-4′a,H-7b,H-14eq),1.46(s,3H,12-CH3),1.38-1.30(m,1H,H-4′b),1.29(s,3H,6-CH3),1.24 -1.13(m,6H,2-CH3,5′-CH3),1.13-0.99(m,9H,10-CH3,8-CH3,4-CH3),0.81(t,J=7.5Hz,3H,15-CH3). 13C NMR(CD3OD,100MHz)δ:174.94,157.28,156.77,101.73,82.47,79.92,78.61,78.09,77.22,75.17,70.53,68.67,68.51,68.16,64.61,60.16,46 .97,43.17,42.13,41.01,39.46,38.11,37.84,36.70,35.98,30.79,29 .53,21.61,20.27,20.01,18.52,18.36,14.01,11.44,9.85,9.40,8.02.
[0301] Preparation Example 13: Synthesis of Reference Standard TE-802
[0302] TE-802 was synthesized according to the method described in the Journal of Antibiotics, 2001, 54(8):664. as a control. The spectrum was consistent with that in the literature, as shown below: HRMS(ESI)(M+H) + m / z 638.39845, calcd for C 33 H 56 N3O9 638.40111. 1H NMR (CDCl3, 400MHz) δ: 4.95 (dd, J=2.5Hz, 10.5Hz, 1H, H-13), 4.30 (d, J=7.3Hz, 1H, H-1′), 4.21(d,J=8.6Hz,1H,H-5),3.99(dt,J=2.8Hz,14.4Hz,1H,CH2),3.88-3.74(m,3H,CH2,H- 2),3.73(d,J=1.5Hz,1H,H-11),3.59-3.50(m,1H,H-5′),3.47(s,1H,2′-OH),3.19(dd,J= 7.3Hz,10.2Hz,1H,H-2′),3.14-3.03(m,1H,H-4),3.01-2.89(m,1H,CH2),2.80-2.64(m,5 H,6-O-CH3,H-10,H-8),2.51-2.39(m,1H,H-3′),2.26(s,6H,-N(CH3)2),1.97-1.85(m,1H ,H-14ax),1.74-1.63(m,2H,H-4′a,H-7a),1.62-1.45(m,5H,H-7b,H-14eq,12-CH3),1.39 (d,J=6.8Hz,3H,2-CH3),1.36(s,3H,6-CH3),1.29(d,J=7.5Hz,3H,4-CH3),1.26-1.18(m, 7H, 10-CH3, 5′-CH3, H-4′b), 1.05 (d, J=7.0Hz, 3H, 8-CH3), 0.86 (t, J=7.4Hz, 3H, 15-CH3). 13 C NMR(CDCl3,100MHz)δ:204.24,181.09,169.55,156.08,103.91,81.52,79.19,78.52,76.51,70.35,69.58,65.90,59.94,51.21, 49.60,49.10,48.14,42.86,42.36,40.26,38.60,36.36,28.16,22.10,21.19,19.64,19.14,16.46,14.40,12.86,10.90,10.45.
[0303] In vitro antibacterial activity assay
[0304] According to the standards recommended by the Clinical and Laboratory Standards Institute (CLSI, 2010), the in vitro antibacterial activities of some target compounds against susceptible Streptococcus pneumoniae ATCC49619, MEF efflux-resistant Streptococcus pneumoniae PU-09, constitutive ERM-resistant Streptococcus pneumoniae 07P390, constitutive ERM-plus-MEF-resistant Streptococcus pneumoniae 05O173, induced ERM-B resistant Streptococcus pyogenes 01-968, constitutive ERM-A resistant Streptococcus pyogenes 12-206, induced ERM-A resistant Staphylococcus aureus PU32, constitutive resistant Staphylococcus aureus 15B196, PU20, Haemophilus influenzae ATCC49247, azithromycin-resistant Haemophilus influenzae 21B402, and catamorrah 13L332 were determined using the broth dilution method. Each bacterial strain was plate-transfected and purified before the experiment, and fresh bacterial cells were used for testing. Standard strains were used as quality control bacteria for each experiment; antibiotic-free bacterial solutions were used as growth controls for the test strains. The minimum inhibitory concentration (MIC) was determined using the broth two-fold dilution method. Antibiotic concentrations ranged from 0.008 μg / mL to 256 μg / mL, with a final bacterial concentration of approximately 5 × 10⁻⁶. 5 CFU / ml.
[0305] The measurement results are shown in Table 1-3:
[0306] The structural formula of compound MCX-162 is shown below:
[0307]
[0308] Table 1: Antibacterial activity (MIC, μg / mL) of the compounds of this invention against Streptococcus pneumoniae and Streptococcus pyogenes
[0309]
[0310] Table 2: Antibacterial activity (MIC, μg / mL) of the compounds of this invention against Haemophilus influenzae, Staphylococcus aureus, and Moraxella catarrhalis.
[0311]
[0312]
[0313] The test results in Tables 1 and 2 show that the antibacterial activity of the compounds of the present invention is superior to that of clarithromycin, MCX-162, TE-802 and telithromycin.
[0314] Table 3. MIC (MIC, μg / mL) of the compounds of this invention against engineered Escherichia coli SQ110 series.
[0315]
[0316] SQ110 DTC *Escherichia coli* is an engineered bacterium used to study the mechanisms of action of antibiotics such as macrolides. Macrolides easily cross the bacterial outer membrane and possess only one set of ribosomal RNA operators. When the ribosomal or topoisomerase action sites of SQ110DTC are mutated, the MIC of antibiotics acting on those sites increases, exceeding the MIC against unmutated SQ110DTC bacteria, such as the positive control drugs clarithromycin, telithromycin, and ciprofloxacin. This indicates that clarithromycin and telithromycin act only on the ribosome, while ciprofloxacin acts only on the topoisomerase. Table 3 shows that the MIC changes are not significant when the compounds in this application are mutated at the ribosomal A2058 site or the topoisomerase Ser83Leu site; however, when both sites are mutated, the MIC increases. This proves that the compounds act not only on the ribosome but also on the topoisomerase, making them dual-target compounds. Such compounds are unlikely to induce bacterial mutations during use, thus possessing high practical value.
[0317] The foregoing has described exemplary embodiments of the present invention. However, it should be understood that the scope of protection of the present invention is not limited to the above exemplary embodiments. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the scope of protection of the present invention.
Claims
1. A compound of formula (I), stereoisomers, tautomers, isotopically-labeled forms, nitroxides, solvates, polymorphs, metabolites, esters, pharmaceutically acceptable salts or prodrugs thereof: ###0001### wherein: X represents O or NH; A represents O or NR; R represents H or a C1-C6 alkyl group; each R3 is the same or different, independently selected from H, halogen, OH, CN, NO2, NH2, COOH, -R4, -R4-R5; Z represents CH2, NH or O; D represents CH or N; m is selected from an integer from 0 to 10; for example, an integer from 0 to 8, such as 1, 2, 3, 4 or 5; n is selected from an integer from 0 to 10, for example, an integer from 0 to 6, such as 0, 1, 2 or 3; preferably, A is selected from NR, R is selected from methyl, ethyl, propyl, butyl, pentyl, hexyl, -methyl-NH2, -ethyl-NH2, -propyl-NH2, -butyl-NH2, -propyl-imidazole-pyridine, -butyl-imidazole-pyridine, -butyl-triazole-pyridine, -butyl-triazole-aminobenzene, -pentyl-imidazole-pyridine; or, when X represents NH, A represents NR, R is selected from ethyl, propyl or butyl, the end of the ethyl, propyl or butyl group is connected to X to form a ring; or, when X represents NH, A represents NR, R is selected from ethyl, the end of the ethyl group is connected to X to form a ring; preferably, Z represents CH2 or O; preferably, Y represents ethynyl, propynyl, pyrrolidinyl or piperidinyl; preferably, R1 represents methyl, ethyl, cyclopropyl, fluorocyclopropyl; preferably, R2 represents H, halogen, for example, selected from fluorine, preferably substituted at the 6-position; preferably, m is selected from 2, 3, 4 or 5; preferably, n is selected from 0 or 1 or 2. The compound of formula (I) has the structure of formula (I-1): ###0002### wherein: R' is selected from -CH2CH2-, -CH2CH2CH2-, -CH(CH3)CH2-, -CH(CH3)CH(CH3)-, -C(CH3)(CH3)CH(CH3)-, -C(CH3)(CH3)CH2-, -C(CH3)(CH3)C(CH3)(CH3)-; or, the compound of formula (I) has the structure of formula (I-2): ###0003### wherein: R, Z, Y, D, R1, R2, m, n have the definitions as described in claim 1. The compound of formula (I) has the structure of formula (II): ###0004### wherein: X, A, Z, R1, R2, m, n have the definitions as described in claim 1. The compound of formula (I) has the structure of formula (II-1): ###0005### or, the compound of formula (I) has the structure of formula (II-2): ###0006### wherein: R, Z, R1, R2, m, n have the definitions as described in claim 1. The compound of formula (I) has the structure of formula (III): ###0007### wherein: X, A, Z, R1, R2, m, n have the definitions as described in claim 1. The compound of formula (I) has the structure of formula (III-1): ###0008### or, the compound of formula (I) has the structure of formula (III-2): ###0009### wherein R represents C1-C6-alkyl, optionally substituted by one, two or more R3 1-6 C1-C6-alkyl, -3-10 membered heterocyclyl-C 1-6 C1-C6-alkyl, -CH=NO-C 1-6 C1-C6-alkyl; R4, R5represent C 6-10 aryl or 5-10 membered heteroaryl, which C 6-10 The aryl or 5-10 membered heteroaryl can be unsubstituted or substituted by one, two or more halogen, OH, CN, NO2, NH2, COOH; Alternatively, when X represents NH, A represents NR, and R is selected from C 1-6 alkyl, C 1-6 alkyl is attached to X to form a ring; Y represents C 2-6 alkynyl or 3-10 membered heterocyclyl containing one heteroatom selected from N, O, or S; R1represents C 1-6 alkyl, C 3-10 cycloalkyl, 3-10 membered heterocyclyl, C 6-10 aryl or 5-10 membered heteroaryl; said C 1-6 alkyl, C 3-10 cycloalkyl, 3-10 membered heterocyclyl, C 6-10 aryl or 5-10 membered heteroaryl can be unsubstituted or substituted by one, two or more halogen, OH, CN, NO2, NH2, COOH; R2represents H, halogen, C 1-6 alkyl or C 1-6 alkoxy; and with the proviso that A is not O when Y represents C 2-6 alkynyl; Preferably, A is selected from O or NR, R is selected from C 1-6 alkyl, -C 1-6 alkyl-NH2, -C 1-6 alkyl-R4-R5; R4, R5are selected from C 6-10 aryl or 5-10 membered heteroaryl, wherein at least one heteroatom is selected from N, for example 1, 2 or 3 heteroatoms are selected from N; for example phenyl, naphthyl, pyridyl, imidazolyl, triazolyl, benzoquinolyl, diazanaphthyl, thiazolyl; Preferably, A is selected from NR, R is selected from methyl, ethyl, ethyl-NH2, Preferably, Y represents ethynyl, (as ), 2. The compound, stereoisomer, tautomer, isotopically labeled, nitroxide, solvate, polymorph, metabolite, ester, pharmaceutically acceptable salt, or prodrug thereof of claim 1, wherein, wherein R' represents -C 1-6 alkyl-, Z, Y, D, R1, R2, m, n have the definitions given in claim 1; 3. The compound, stereoisomer, tautomer, isotopically labeled, nitroxide, solvate, polymorph, metabolite, ester, pharmaceutically acceptable salt, or prodrug thereof of claim 1, wherein, 4. The compound, stereoisomer, tautomer, isotopically labeled, nitroxide, solvate, polymorph, metabolite, ester, pharmaceutically acceptable salt, or prodrug thereof of claim 1, wherein, wherein R' represents -C 1-6 alkyl-, Z, R1, R2, m, n have the definitions as in claim 1; 5. The compound, stereoisomer, tautomer, isotopically labeled, nitroxide, solvate, polymorph, metabolite, ester, pharmaceutically acceptable salt, or prodrug thereof of claim 1, wherein, 6. The compound, stereoisomer, tautomer, isotopically labeled, nitroxide, solvate, polymorph, metabolite, ester, pharmaceutically acceptable salt, or prodrug thereof of claim 1, wherein, wherein R' represents -C 1-6 alkyl-, Z, R1, R2, m, n have the definitions as in claim 1; wherein R, Z, R1, R2, m, n have the definitions as described in claim 1.
7. The compound, stereoisomer, tautomer, isotopically labeled, nitroxide, solvate, polymorph, metabolite, ester, pharmaceutically acceptable salt, or prodrug thereof of claim 1, wherein, The compound of formula (I) is selected from the following specific compounds:
8. A pharmaceutical composition comprising the compound of formula (I), stereoisomers, tautomers, isotopically-labeled, nitroxides, solvates, polymorphs, metabolites, esters, pharmaceutically acceptable salts or prodrugs thereof as described in any one of claims 1-7.
9. Use of the compound of formula (I), stereoisomers, tautomers, isotopically-labeled, nitroxides, solvates, polymorphs, metabolites, esters, pharmaceutically acceptable salts or prodrugs thereof as described in any one of claims 1-7 and the pharmaceutical composition of claim 8 for the preparation of an anti-pathogenic microorganism medicament.
10. Use according to claim 9, characterized in that, The anti-pathogenic microorganism medicament is used for inhibiting or killing at least one of the following pathogenic microorganisms: Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, Staphylococcus aureus, Staphylococcus epidermidis, Moraxella catarrhalis, Mycoplasma or Chlamydia; Preferably, the anti-pathogenic microorganism medicament is used for inhibiting or killing at least one of the following strains of erythromycin sensitive or different drug resistance types: sensitive Streptococcus pneumoniae, constitutive drug resistant Streptococcus pneumoniae, efflux drug resistant Streptococcus pneumoniae, sensitive Staphylococcus aureus, induced drug resistant Staphylococcus aureus, constitutive drug resistant Staphylococcus aureus, sensitive Streptococcus pyogenes, efflux drug resistant Streptococcus pyogenes, induced drug resistant Streptococcus pyogenes, constitutive drug resistant Streptococcus pyogenes, Haemophilus influenzae, Moraxella catarrhalis.
